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Clinically used prosthetic vascular grafts fail frequently from thrombosis and anastomotic 
stenosis in small diameter applications. A bio-inductive vascular graft could improve 
performance by remodeling into an artery-like tissue after implantation, thereby approaching the 
mechanical and physiological function of healthy arteries. We hypothesized that a bio-inductive 
vascular graft must remodel rapidly to promote neoartery formation rather than a classical 
foreign body response. To test this hypothesis, we developed vascular grafts made from 
microporous foams of a fast-resorbing elastomer composited with a slower-resorbing polymer 
sheath for mechanical support. Composite grafts performed well (80% patency) as infrarenal 
abdominal aorta interposition grafts in rats, and within 90 days remodeled into neoarteries which 
approached native arteries in mechanical compliance and tissue architecture.  
Following this encouraging proof-of-concept, the objective of this dissertation is to assess 
the potential of our vascular graft design to translate toward clinical application. To assess 
translational potential, we first assessed the long-term performance of the microporous foam 
composite design in rats at 1-year post-implantation. We found that the resultant neoarteries 
maintained 80% patency, contained the same amount of mature elastin as native arteries, and 
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possessed nerves resembling native perivascular nerves. To improve clinical feasibility of the 
design, we next sought to improve graft surgical handling and simplify the fabrication process, 
which we achieved by developing a novel technique to fabricate grafts from electrospun PGS 
microfibers. We then implanted electrospun microfiber grafts in a mouse model to assess 
whether they retained the favorable long-term performance observed in microporous PGS foam 
grafts. Electrospun grafts achieved 100% patency up to 1 year post-implant, but all grafts dilated 
within that time. Remodeled electrospun grafts retained polymer residues at 1 year, thereby 
demonstrating slower resorption than the original foam design, likely due to reduced pore size. 
An elastin-rich neotissue containing contractile smooth muscle cells developed on the luminal 
surface of the graft within 3 months, but macrophages persisted at 1 year, and calcification 
occurred in all neoarteries at late term. Taken together, these results suggest that a PGS-based 
vascular graft can achieve excellent long-term performance, but efforts to improve translational 
potential must preserve fast in-host remodeling. 
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1.0  INTRODUCTION 
The mission to construct a functional blood vessel substitute has captivated the scientific 
community for the past three decades. This field has historically drawn such strong and 
persistent interest for two main reasons: (1) the potential for large clinical impact, and (2) the 
technical challenge of building a tissue with such demanding mechanical and biological 
performance requirements. Because of its potential impact on both medicine and science, such a 
blood vessel substitute has been considered a “holy grail” of cardiovascular research [1].  
Importantly, solving (2) does not necessarily achieve (1). For a vascular conduit to 
potentially help patients, its likeness to a living blood vessel is not alone sufficient. Production 
costs, lead time, surgical handling, and long-term performance (to name a few) must be within 
the realm of clinical feasibility for the implant to have a chance of reaching patients. This 
dissertation describes the development of a bio-inductive vascular graft with such considerations 
in mind.  Thus to understand the rationale behind our approach, one must understand both the 
clinical significance and technical challenges of a bio-inductive vascular graft. To this end, the 
introductory chapter will begin by outlining the clinical importance of vascular grafts. The 
chapter will then review progress in the field of tissue engineered and bio-inductive vascular 
substitutes, and conclude the review with an introduction to our laboratory’s own approach. 
Lastly, this chapter will introduce the objective and specific aims of this dissertation. 
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1.1 CLINICAL SIGNIFICANCE 
Vascular grafts are conduits which restore or reroute blood flow. Vascular grafts treat a number 
of clinical conditions of high incidence, impacting approximately 600,000 patients per year in 
the United States [2-4]. The two types of vascular grafts most commonly used clinically are 
autografts and prosthetic grafts. Autografts are autologous blood vessels harvested from the 
patient and transplanted ectopically. Autografts have superior patency to prosthetic grafts in most 
applications [5, 6]. Prosthetic grafts are made from permanent synthetic materials, most 
commonly ePTFE (Goretex) or PET (Dacron). Allografts and homografts are also considered 
prosthetic grafts, but are used sparingly in clinic and will not be reviewed in this section. The 
term “vascular graft” is often used clinically to describe prosthetic grafts only, but for simplicity 
this dissertation will define a vascular graft as any conduit which restores or reroutes blood flow. 
Prosthetic grafts have inferior patency to autografts in small diameter (< 6 mm) applications, but 
are used frequently in large diameter settings where performance is more comparable [7]. The 
most common application of vascular grafts is for arterial bypass, in which the graft reroutes 
blood flow around a narrowed artery to restore perfusion to ischemic tissue distal to the affected 
artery. Narrowing in arteries is often caused by atherosclerosis or complications of diabetes. 
Arterial bypass of the coronary arteries, known as CABG (coronary artery bypass grafting), is the 
most common bypass procedure with nearly 400,000 cases per year in the United States [2]. 
CABG procedures critically impact patient health, as the graft restores blood flow to the 
myocardium to treat life-threatening ischemic heart disease. Autografts are the standard of care 
for CABG procedures, with the internal mammary artery demonstrating the best clinical 
performance [8]. Prosthetic grafts are unsuitable for CABG procedures due to the small diameter 
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of coronary arteries. Clinical use of prosthetic grafts for CABG yields poor patency rates due to 
thrombosis and intimal hyperplasia [9]. 
Arterial bypass for the lower extremities, known as peripheral artery bypass, is performed 
in 100,000 patients per year in the United States [3] and has substantial healthcare impact, as it 
prevents limb loss and other ischemia-induced morbidities. Autografts, most commonly the 
greater saphenous vein, are preferred in peripheral artery bypass, but prosthetic grafts are used 
when autografting is not possible due to previous harvest, vascular disease in the vessel to be 
autografted, or when the length of the occlusion to be bypassed is too large [10]. Prosthetic grafts 
demonstrate inferior patency to autografts in below-the-knee peripheral bypass [11], yet are used 
in up to 20% of cases due to insufficient available length of saphenous vein for autografting [10]. 
Peripheral prosthetic vascular grafts fail by thrombosis and neointimal hyperplasia at the 
anastomoses [12]. 
Vascular grafts also direct blood flow for purposes other than reperfusion. Hemodialysis 
grafts link a patient’s artery directly to a vein to achieve flow rates sufficiently rapid for 
hemodialysis, a procedure in which a patient’s blood is detoxified outside of the body then 
returned. The preferred method of connecting the patient’s artery to vein is by surgically creating 
an arteriovenous fistula, but prosthetic hemodialysis grafts are required when patients lack a 
healthy, suitably sized vein. Each year over 35,000 patients in the United States receive an 
ePTFE prosthetic hemodialysis graft [4, 13]. The clinical need to improve prosthetic 
hemodialysis graft performance is especially large, as 50% of grafts fail within 1 year due to 
stenosis, thrombosis, and infection [4]. 
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Vascular grafts also treat a number of lower incidence conditions, but these have a major 
impact on the health of those affected. EC TCPC (Extra cardiac total cavopulmonary 
connections) are vascular grafts used to treat pediatric patients with single ventricle anomalies, a 
grouping of congenital heart defects which affect 8,000 patients in the US [2] and cause 70% 
mortality if left untreated [14]. EC TCPCs passively connect the vena cava directly to the 
pulmonary circulation reroute deoxygenated blood directly into the pulmonary artery, thereby 
preventing premature re-entry of deoxygenated blood into the systemic circulation. Autografts 
are preferred but rarely available. Consequently, ePTFE prosthetic grafts are the standard of care 
for EC TCPC [15]. These grafts fail frequently from thrombosis and lack growth potential, 
necessitating additional surgery when the patient outgrows the vascular graft [14]. Vascular 
grafts are also used to replace or reconstruct vessels damaged in traumatic injury [16, 17]. 
Saphenous vein grafts are preferred, as prosthetic grafts fail frequently from thrombosis and 
infection [16, 17]. Vascular grafts also connect transplanted tissues to implant site vasculature 
when native vessel stumps are too short. The small diameter of these native vessels necessitate 
vein grafts rather than prosthetic grafts to achieve adequate patency [18]. 
The opportunity to improve clinical outcomes for vascular grafting is substantial, as there 
are disadvantages to the use of both autografts and prosthetic grafts. Prosthetic grafts failures can 
be attributed to the persistence of long-lasting synthetic materials, which cause thrombosis, 
promote intimal hyperplasia at the native anastomoses due to compliance mismatch [19], and 
harbor late-term infection [20]. Autografts are limited in supply, and their harvest causes donor 
site morbidity and requires additional surgical manipulation. Additionally, despite often being 
the standard of care, vein autografts fail from thrombosis and intimal hyperplasia due to harvest-
induced endothelial injury and adverse remodeling in response to arterial pressure [21]. 
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To address the disadvantages of both prosthetic grafts and autografts, many groups 
including our own laboratory have sought to develop a vascular graft whose final state is a 
living, artery-like tissue. These grafts have the potential to outperform prosthetic vascular grafts 
by emulating arterial physiology and avoiding long-lasting materials. In pediatric patients, such 
grafts could theoretically grow with the patient, thereby circumventing the need for revision 
surgeries [14]. Ideally, if they can match autograft performance, such grafts could be used in 
their place, thereby circumventing harvest surgery and donor site morbidity. The next section 
will review such efforts to develop the ideal vascular graft, then introduce our own laboratory’s 
approach which serves as the basis for the work described in this dissertation.    
1.2 BIO-INDUCTIVE AND TISSUE ENGINEERED GRAFTS 
Attempts to improve the patency of prosthetic grafts have shown limited success. These efforts 
employ surgical modifications, alternate non-resorbable materials, surface functionalization, 
endothelial cell seeding, and localized drug delivery ([12] for review). Today a range of 
clinically available prosthetic grafts employ some of these strategies, including heparin or carbon 
surface modification to reduce thrombogenicity, impregnation with antimicrobials, and use of 
compliant materials [12].  Though these approaches show promise, to date no prosthetic graft has 
demonstrated equivalent performance to autografts in small diameter applications. 
In the absence of a prosthetic graft matching autograft performance, research groups 
across the world have sought to develop a vascular graft whose final state is a living artery-like 
vessel. Such a graft would be the ideal vascular substitute, as living arteries are optimally 
designed by nature to conduct blood flow under physiologic conditions. To resist thrombosis, 
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native arteries present a confluent layer of endothelial cells as the blood-contacting surface, 
which actively prevent thrombosis and platelet adhesion by presenting heparin sulfate, tissue 
plasminogen activator (tPA), thrombomodulin, prostacyclin, and nitric oxide. [22] Elastin-rich 
elastic laminae impart physiologic mechanical compliance in arteries, which prevents the 
hemodynamic disruptions responsible for neointimal hyperplasia in compliance mismatched 
vascular grafts [19]. 
To realize a living artery-like conduit, the research community has employed both tissue 
engineering and bio-inductive approaches. Tissue engineering techniques seek to develop a 
living artery-like conduit outside of the body, typically by growing and conditioning cell-rich 
tissue constructs in bioreactors in vitro. In contrast, bio-inductive approaches employ resorbable 
conduits as temporary scaffolding meant for the host’s cells to infiltrate and remodel into a living 
artery in situ. This section will review progress in each type of approach, then introduce our own 
laboratory’s fast-remodeling bio-inductive strategy to set the foundation for the work described 
in this dissertation. 
1.2.1 Tissue engineered vascular grafts 
Tissue engineering techniques seek to develop a living artery-like conduit outside of the body. 
Tissue engineered vascular grafts (TEVG) comprised substantially of vessel-like tissue are 
attractive because they could potentially require little host remodeling to assume vessel 
properties and physiologic function. The field of vascular tissue engineering began in 1986 when 
Weinberg and Bell produced a living tubular tissue in vitro from vascular smooth muscle cells, 
endothelial cells, and fibroblasts in a collagen gel. [23] Since then, researchers have examined 
the effectiveness of various materials, cells, and culture conditions for in vitro TEVG production. 
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Collagen gel-based TEVG have been strengthened through natural crosslinking [24], 
biochemical stimulation [25], mechanical stimulation [26-28], and reinforcement with other 
materials [29-31]. He and Matsuda reinforced collagen gel TEVGs with polyurethane sleeves 
that remained patent in dog carotid arteries for up to 6 months [32]. Fibrin gel-based TEVGs 
were pioneered by Grassl et al. [33], and have been similarly strengthened [34-41]. Swartz et al. 
implanted fibrin TEVGs made from smooth muscle and endothelial cells into sheep jugular veins 
with 100% patency at up to 15 weeks [40]. Koch et al. implanted PLA-reinforced fibrin TEVGs 
into sheep carotid arteries with 100% patency at up to 6 months, though stenosis was seen in one 
explant [42]. Tranquillo’s group developed implantable fibrin TEVGs from human fibroblasts 
using pulsatile flow mechanical conditioning for 7-9 weeks [38], and recently demonstrated that 
similarly constructed TEVGs could be devitalized for off-the-shelf use. Devitalized grafts 
matched native artery compliance, and demonstrated complication-free remodeling into elastin-
rich neoarteries in 24 weeks as ovine femoral interposition grafts [43]. Preseeding devitalized 
grafts with blood outgrowth endothelial cells substantially reduced neoartery wall thickness, 
likely due to accelerated deposition of basement membrane [44]. Esterified hyaluronic acid 
(HYAFF-11) [45] and silk fibroin [46-48] have also showed promise for developing TEVGs in 
vitro. Decellularized blood vessels have also been substantially recellularized in vitro. Yang et al. 
demonstrated that bioreactor conditioning of dog carotid arteries recellularized with arterial cells 
produced TEVGs with 100% patency at up to 6 months as canine carotid grafts [49]. Neff et al. 
used a similar approach to produce sheep carotid grafts that responded to vasomotor agents [50]. 
 Niklason et al. developed the first highly cellular TEVG in vitro based on a degradable 
synthetic material. This work combined a PGA mesh with smooth muscle and endothelial cells 
in vitro under mechanical and biochemical stimulation to produce TEVGs that remained patent 
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in pigs for up to 24 days [51]. Niklason’s group recently adapted this strategy to produce 
devitalized TEVGs with off-the-shelf availability by decellularizing the TEVGs after 10 weeks 
of bioreactor culture. Devitalized grafts made from porcine cells had 100% patency at 30 days as 
pig carotid bypass grafts [52], and grafts made from human cells had 88% patency for up to 6 
months as baboon arteriovenous shunts and 83% patency for dog carotid and coronary bypasses 
[53]. Using human cells, Humacyte’s devitalized TEVG is now being clinically trialed in the US 
as above-knee femoro-popliteal bypass grafts [54] and hemodialysis grafts [55, 56]. Zund’s 
group showed that TEVGs coated with poly-4-hydroxybutrate, seeded with myofibroblasts, and 
matured in a pulsatile bioreactor yielded 100% patency at 2 years post-implant as sheep 
pulmonary artery grafts [57]. Long-term follow-up at 4.5 years demonstrated complete material 
resorption without major complication, and suggests that seeded cells were replaced by host cells 
[58].  
Cell seeding with short-term culture can improve the patency of resorbable vascular 
grafts without the long lead times and production costs of traditional tissue engineering. This 
approach is typically still considered “tissue engineering,” but should be distinguished from 
efforts to produce mature vessel-like tissues in vitro. Many groups have seeded grafts with 
endothelial cells and/or smooth muscle cells to improve graft patency [59-65]. A wide range of 
stem and progenitor cells have also been shown to improve graft patency and remodeling ([66] 
for review). Breuer and Shin’oka’s groups demonstrated that bone marrow mononuclear cells 
improve the patency of degradable polyester grafts in both small and large animal models [67-
69]. These grafts have been used clinically with good patency as EC-TCPC conduits [70], and 
are currently in Phase I clinical trials in the US [71, 72]. Hashi et al. showed that human 
mesenchymal stem cells can improve the patency of PLA grafts in rat common carotid arteries 
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[73]. Vorp’s group demonstrated that muscle derived stem cells [74] and pericytes [75] improve 
the patency of PEUU grafts in rat abdominal aortas. These grafts used a novel rotational vacuum 
seeding technique to improve the number and distribution of seeded cells [76]. Zhou et al used 
endothelial progenitor cells to improve the patency of decellularized canine carotid arteries when 
used as dog carotid grafts [77]. In a sheep model, Tillman et al. demonstrated translational 
feasibility of using decellularized arteries seeded with endothelial cells for hemodialysis access. 
Grafts demonstrated healing potential after needle puncture, as host cells infiltrated puncture 
sites [78]. For clinical translation of strategies which employ autologous stem cells, the likely 
potency of each patient’s cells should be carefully considered. In elderly patients, adipose-
derived mesenchymal stem cells demonstrated inferior ability to promote smooth muscle cell 
migration or differentiate into smooth muscle in vitro [79].   
“Self-assembled” TEVGs are developed entirely from cells and the matrix they produce. 
These TEVGs have the potential to assume especially artery-like structure and function in vitro 
because their assembly avoids the interference of foreign materials with neotissue formation. 
Autologous self-assembled TEVGs might elicit less inflammation than other tissue engineered 
strategies, as they are completely void of foreign material. The first self-assembled TEVG was 
developed by L’Heureux et al. in 1998 by rolling sheets of smooth muscle and fibroblasts into a 
tube to produce implantable grafts [80]. Refining this approach to use only human fibroblasts 
[81] led to the development of autologous self-assembled hemodialysis grafts that performed 
well in clinical trials [82]. Recently, this approach has employed devitalization of the TEVGs so 
they are available off-the-shelf [83]. Allogeneic devitalized TEVGs performed well in 3 patients 
at up to 11 months as hemodialysis grafts, with no evidence of dilation or immune reaction [84]. 
Another promising self-assembly approach is bioprinting, in which cells are deposited by a 
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printer into three-dimensional structures [85]. This technology is still in its early stage but has 
already made TEVGs with tunable geometries [86]. Another approach related to self-assembly is 
the “Sparks Mandril” approach in which a tubular fibrous tissue for vascular grafting is 
generated by implanting a mandrel subcutaneously and then isolating the fibrous capsule. This 
method was pioneered in part by Schilling et al., who implanted them as dog abdominal aorta 
grafts with excellent patency at 3 years post-implant [87]. Sparks used a similar strategy and 
began implanting human patients with variable results [88, 89]. This approach was adapted by 
Campbell’s group, who implanted silastic tubing in the peritoneal cavity of animals and used the 
granulation tissue as vascular grafts. These grafts demonstrated 65% patency in rat arteries and 
70% patency in rabbit arteries at 4 months [90]. Adaptation to dog femoral grafts yielded 83% 
patency at 6.5 months and demonstrated constructive graft remodeling [91]. 
1.2.2 Bio-inductive vascular grafts 
Much research has sought to develop a bio-inductive small diameter vascular graft that can 
regenerate a host blood vessel in situ. By harnessing the host’s own neotissue generating 
capacity, bio-inductive grafts combine the off-the-shelf availability of prosthetic grafts with the 
patency and growth potential of autografted vessels. They also have a substantial advantage over 
tissue engineered grafts in production cost by circumventing the need for cell culture and 
bioreactor maturation. Bio-inductive vascular grafts were first investigated in the late 1970’s and 
1980’s. Early work employed acellular grafts made fast-resorbing polyesters and polyurethanes. 
Poly(glycolic acid) (PGA) based grafts implanted as short aorta grafts in pigs experienced near-
complete material resorption between 40 and 90 days, and remodeled into neoarteries with 
artery-like tissue architecture, albeit elastin was less organized than the native elastic lamina 
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[92]. Testing of longer, large diameter aorta bypass grafts revealed that grafts up to 15 cm long 
could remodel into neoarteries without rupture, though longer grafts failed by rupture within 22 
days [93]. The first small diameter PGA grafts were implanted by Greisler and colleagues in 
1982 as rabbit aorta interpositions. These grafts remodeled into neoarteries over a similar time 
course, but elastin deposition was minimal, and both dilation and intimal hyperplasia were 
observed at 11% and 13% incidence, respectively [94, 95]. Slower-degrading polydioxanone 
grafts resorbed within 6 months and reduced rates of aneurysmal dilatation, but also reduced the 
rate of tissue ingrowth [96]. Concurrent to research in fast-resorbing polyester grafts, fast-
resorbing polyurethanes with physiologic compliance were investigated for their capacity to 
generate neoarteries while avoiding compliance mismatch. Initial testing of polyurethane grafts 
as pig aorta grafts showed complete material resorption within 4 months, and grafts and 
remodeled into neoarteries with organized elastic fibers [97]. Curiously, a similar polyurethane 
graft demonstrated high propensity for thrombosis, requiring aspirin or high-lipid diet to recover 
patency [98]. 
Despite the early promise of faster-resorbing bio-inductive grafts, most subsequent work 
employed slower resorbing materials, likely to assure mechanical stability for the duration of the 
remodeling process. These materials included degradable polyesters [92-96, 99-101] or 
decellularized extracellular matrix [102-105]. Since then, some bio-inductive grafts have shown 
promise in vivo. Huynh et al. implanted acellular collagen-based grafts as rabbit carotid bypasses 
that demonstrated constructive graft remodeling and 100% patency at 90 days [106]. Yokota et 
al. implanted composites of polyglycolic acid (PGA) and poly-L-lactic acid (PLA) in dog carotid 
arteries with 100% patency at up to 12 months and vessel-like tissue covering the graft lumen 
[107]. PLA has also been functionalized with hirudin to reduce thrombogenicity, leading to 
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improved patency in rat carotid arteries [108]. Recent work by Shinoka’s group demonstrated 
that nanofibrous PLA grafts demonstrate favorable patency as mouse abdominal aorta grafts, 
with neoartery-like tissue formation in the luminal side of the graft [109]. Increasing PLA graft 
pore size reduced calcification and improved neotissue formation in elastin and smooth muscle 
content [110]. Soletti et al. developed rat aorta grafts from poly(ester urethane)urea (PEUU) 
coated with phospholipid to improve hemocompatibility, yielding 92% patency at 8 weeks and 
patent grafts at up to 24 weeks [111]. Schima’s group developed microfibrous grafts made 
biodegradable thermoplastic polyurethane (TPU), and achieved superior patency to ePTFE grafts 
as rat abdominal aorta interpositions at 1 year post-implantation, with no sign of neointimal 
hyperplasia and moderate resorption of graft material [112]. 
Recently, several research teams including our own have revisited the concept of fast-
remodeling, cell-free bio-inductive vascular grafts. Cortivo’s group demonstrated that nonporous 
conduits made from esterified hyaluronic acid remodel rapidly into neoarteries containing elastin 
fibers in rats [113, 114] and pigs [115], though patency in the porcine model was limited by 
thrombosis and intimal hyperplasia. Breuer’s group demonstrated in 2015 that combining PLCL-
sealed PGA grafts with localized delivery of an inhibitor for TGF Beta receptor can achieve the 
same neovessel patency as cell-seeded grafts [116]. Fast-remodeling bio-inductive grafts have 
also reached the clinic. In 2015 European medical device company Xeltis AG began a phase I 
clinical trial testing a proprietary fast-resorbing graft as EC-TCPCs in pediatric patients with 
single ventricle anomalies [117]. 
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1.2.3 Fast-remodeling composite of PGS and PCL 
Our laboratory developed our own bio-inductive vascular graft in 2012 [118]. We chose a bio-
inductive approach rather than tissue engineering for the advantages in production time and 
costs, which improve the graft’s potential for clinical translation (Figure 1). In determining the 
design, we observed from literature that neoarteries with the most likeness to native arteries were 
formed from either fast-resorbing bio-inductive grafts or tissue engineered grafts comprised 
primarily of fast-resorbing materials. Consequently, we hypothesized that for a bio-inductive 
vascular graft to promote neoartery formation rather than fibrosis and prolongued inflammation, 
the graft material must resorb rapidly. We chose PGS as the material to comprise the bulk of the 
graft because of its rapid resorption rate in vivo [119], its artery-like mechanical properties [120], 
and its ability to promote substantial elastin production from seeded smooth muscle cells in 
bioreactor conditions in vitro [121].  
 The final graft design was a composite consisting of a fast-resorbing microporous PGS 
core and a sheath of slower resorbing PCL nanofibers (Figure 2). Table 1 reports structural 
specifications of these grafts. The purpose of the microporous PGS core was to enable rapid cell-
infiltration, transduce mechanical forces to cells, and resorb quickly to make way for neoartery 
tissue formation. The nanofibrous PCL sheath served multiple functions: (1) to impart the 
mechanical strength required for the graft to hold suture; (2) to render the graft leak-proof; and 
(3) to protect the early-stage neoartery from dilating as the PGS core degrades. The PGS core 
was fabricated using a solvent casting particulate leaching (SCPL) technique which yields 
seamless microporous tubular scaffolds [122]. The fibrous PCL sheath was applied by 
electrospinning PCL directly onto the PGS core. To distinguish these grafts from others 
described in the dissertation, we abbreviate these design as SCPL PGS-PCL. 
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To evaluate the patency and remodeling potential of these constructs, we implanted 
SCPL PGS-PCL grafts as abdominal aorta interposition grafts in rats. Grafts patency was 80%, 
and patent grafts remodeled rapidly and extensively into neoarteries which were nearly free of 
foreign material by 3 months post-implant. (Figure 3)  Neoarteries demonstrated native or supra-
native mechanical compliance in the physiologic pressure range (11 ± 2.2% vs. 6.7 ± 2.3%; 
Figure 4) and artery-like tissue architecture at in both cell organization (Figure 5) and matrix 
organization (Figure 6). Notably, neoarteries contained 77% of the mass of mature elastin present 
in native arteries, and an equivalent amount of collagen (Figure 6b). Neoarteries resisted 
dilation, as neoartery inner diameter was comparable to age-matched controls at 90 days (Figure 
5c) Taken together, these results support the central hypothesis that rapid remodeling guides in 
situ generation of functional neoarteries rather than fibrotic encapsulation. Further, the favorable 
graft performance and near-absence of residual material suggests the potential for long-term 
neoartery stability. In light of this encouraging proof of concept, the work described in this 
dissertation aims to further assess the translational potential of a fast-remodeling bio-inductive 
vascular graft made from compositing PGS with a slower-resorbing material. 
 
 
 
 
 
Figure 1. Schematic of in-host remodeling of SCPL PGS-PCL bio-inductive graft. 
Direct implantation of a cell-free PGS-PCL composite graft (left), and the proposed remodeling process of the graft 
into a biological neo-artery. Image from [118]. 
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Figure 2. Structure of SCPL PGS-PCL composite grafts. 
SEM images show surface topology of microporous composite grafts. (a) Transverse cross section of graft wall 
shows PCL sheath (left edge) and microporous SCPL PGS core (bulk). Luminal surface is the rightmost edge, scale 
bar 100 µm. Inset: low magnification of graft, scale bar 500 µm. (b) Luminal surface of the PGS core, scale bar 100 
µm. (c) Abluminal surface of the PCL sheath, scale bar 20 µm.  Image from [118]. 
 
 
 
Table 1. Geometric specifications of SCPL PGS-PCL bio-inductive vascular grafts 
 
 
Pore size (µm) 21.2 ± 0.79 
Porosity (%) 81.06 ± 0.97 
Pore interconnectivity (%) 99.99 ± 0.00027 
Inner diameter  (µm) 723 ± 1.33 
Wall thickness (µm) 295 ± 5.52 
Sheath thickness (µm) 15.7 ± 6.11 
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Figure 3. Neoartery formation from SCPL PGS-PCL bio-inductive graft. 
Cell-free bio-inductive grafts remodel in situ into a neoarteries within 3 months of implantation as rat abdominal 
aorta interposition grafts. Left: SEM micrograph of SCPL PGS-PCL composite graft. Inet: Low magnification. 
Right: Neoartery at 3 months post-implant. α-SMA immunostaining (green) indicates smooth muscle cells or 
myofibroblasts. vWF immunostaining (red) suggests a confluent endothelial lining. Right inset: dissecting 
microscope image of neoartery. Image adapted from [118]. 
 
 
 
 
 
 
Figure 4. Neoarteries demonstrate native or supra-native compliance. 
Compliance as a function of luminal pressure, tested ex-vivo. “New grafts” represents unimplanted composite grafts. 
“PGS core” represents new SCPL PGS grafts without the PCL sheath. Error bars represent standard error of the 
mean. Standard errors for new grafts and the PGS core are very small and barely visible at the plotted scale. n = 3 
for neo-arteries and n = 4 for native aortas. Image adapted from [118]. 
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Figure 5. Cellular organization of neoarteries 
(a) H&E staining of the grafts during the transition into a neo-artery. An area of the neo-artery wall containing 
inflammatory cells is marked by (*). The top of the 14-day sample was trimmed to remove the adjoining vein. Image 
merged from a panel of 100x micrographs, scale bar 250 µm. (b) Magnified view of the vessel wall shows ECM 
content and alignment, scale bar 50 µm. (c) Luminal area of remodeling grafts to assess stenosis and aneurysm 
formation. There is no statistical difference between the two groups. (d) Changes in number and organization of 
macrophages (CD68, red). (e) Distribution of M2 macrophages (CD163, red). (f) Number of CD68 and CD163 
positive cells quantifies total macrophage number and the proportion of M2 macrophages. (g) Changes of smooth 
muscle cell (α-SMA, green) organization over time. (h) Distribution of contractile smooth muscle cells (myosin 
heavy chain, red). All the immuofluorescent micrographs were counterstained for nuclei by DAPI (blue), scale bar 
50 µm. Data represent mean ± standard deviation for c and f. Image adapted from [118]. 
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Figure 6. Extracellular matrix organization of neoarteries 
ECM organization and quantification at 90 days. (a) Verhoeff’s, Masson’s trichrome, and safranin O staining show 
elastin (black), collagen (blue), and  glycosaminoglycansin (red). Immunofluorescent staining shows distribution of 
elastin (red), collagen I (green), and collagen III (red). Top: day 90 explant, bottom: native aorta. (b) Quantification 
of elastin (n = 4) and total collagen (n = 4). Data represent mean ± standard deviation. 
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1.3 OBJECTIVES AND SPECIFIC AIMS 
The long-term objective of our laboratory’s research is to develop a bio-inductive vascular graft 
with the improved performance compared to prosthetic vascular grafts, and for which use in a 
clinical setting is feasible. The objective of this dissertation is to assess the translational potential 
of a fast-remodeling, cell-free vascular graft based on fast-degrading elastomer PGS. Driving the 
pursuit of this objective is our central hypothesis, which is consistent with that which we used in 
our previous graft design. We hypothesized that for a bio-inductive vascular graft to promote 
neoartery formation rather than fibrotic encapsulation, the graft material must resorb rapidly. The 
rationale is that rapid clearance of graft material minimizes the interference of foreign material 
with in-host tissue formation and long term homeostasis. 
For a new technology to translate to the clinic, it must demonstrate both desirable clinical 
performance and feasibility of application in a clinical setting. Our laboratory’s recently reported 
bio-inductive vascular graft seems well poised for potential clinical translation, as it 
demonstrated encouraging short-term performance, and its cell-free design suggests clinical 
feasibility in production costs and lead time. However, long term performance remains unknown, 
and grafts require gentle surgical handling, limiting their ease of use in a clinical setting. Thus, to 
further evaluate the graft’s translational potential, the work described in this dissertation pursues 
the following three aims: 
Aim 1 - Long-term performance testing of original design. The objective of this aim is to 
assess the long-term in vivo stability of composite grafts made from microporous SCPL PGS and 
PCL fibers (SCPL PGS-PCL). We hypothesized that at late-term, neoarteries will maintain 
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homeostasis without complication, as material residues are largely absent at 3 months and the 
neotissue is elastin-rich and compliant. To test this hypothesis, we implanted composite grafts 
into rats as abdominal aorta interpositions, and incubated for 1 year. At term, we characterized 
neoarteries extensively both in vivo and ex vivo, and compared with age-matched unoperated 
controls. 
Aim 2 – Improve the translational potential of the design.  The objective of this aim is to 
improve the feasibility of applying PGS-based bio-inductive vascular grafts in a clinical setting. 
We hypothesized that fabricating the PGS core from microfibers will improve surgical handling 
and simplify fabrication. To realize improved translational feasibility, we developed a novel 
method for fabricating PGS microfibers involving electrospinning a range of polymer blends, 
then constructed novel microfibrous grafts. We then compared these grafts to SCPL PGS in 
fabrication time and labor, strength in vitro, and likelihood of successful in vivo implantation. 
Aim 3 - Performance testing of the improved design. The objective of this aim is to 
assess the in vivo performance and remodeling potential of the most promising electrospun graft 
designs developed in Aim 2. We hypothesized that electrospun PGS PCL composites (Espun 
PGS-PCLSheath) would retain the fast-remodeling behavior of the original microporous design in 
spite of reduced pore size, as even nonporous PGS resorbs rapidly in vivo, and nonporous bio-
inductive grafts have previously remodeled into neoarteries. To evaluate graft performance in 
vivo, we joined a multi-institutional collaboration to implant microfibrous vascular grafts as 
mouse abdominal aorta interpositions, and evaluated at up to 1 year post-implant. 
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2.0  LONG-TERM PERFORMANCE OF SCPL PGS-PCL COMPOSITES 
The demonstration of short-term patency is necessary but insufficient for a new vascular graft to 
improve clinical outcomes. Long-term performance must also be favorable, as the ideal vascular 
graft should conduct blood flow for the remaining lifetime of the patient. This chapter presents 
our investigation of the long-term performance of microporous SCPL PGS-PCL composite 
vascular grafts. 
2.1 INTRODUCTION 
Prosthetic vascular grafts are prone to a range of long-term complications, many of which 
require percutaneous or surgical intervention. Neointimal hyperplasia is the most common 
underlying cause of late-term graft occlusive failure [123]. Neointimal hyperplasia describes the 
narrowing of a vessel lumen due to cells migrating into and proliferating within the vascular 
intima. In prosthetic vascular grafts, neointimal hyperplasia occurs in the native vessel at the site 
of anastomosis with the prosthetic graft. Anastomotic occlusion due to neointimal hyperplasia 
reduces patency to as low as 54% at 4 yrs in below-the-knee bypass using prosthetic grafts [124]. 
Late thrombosis in prosthetic grafts most commonly occurs secondary to vessel narrowing due to 
neointimal hyperplasia, and is often the mechanism of final graft occlusion. Infection is another 
serious late-term complication, with incidence ranging from 1 to 6 % ([125] for review). 
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Infection rates are substantially higher in applications more susceptible to infection, such as 
hemodialysis (~20%) [126] and wartime vascular trauma reconstruction (up to 48% in ePTFE 
grafts) [17]. Infection typically requires either graft replacement or salvage techniques, both of 
which are surgical interventions. 
 The persistence of foreign material drives pathologies which substantially contribute to 
these late term failure modes. Foreign material contributes to compliance mismatch, a major 
driver of neointimal hyperplasia, when the graft material is stiffer than native arteries. 
Compliance mismatch is thought to drive neointimal hyperplasia by hemodynamic disruptions 
including turbulent flow and shear stress alteration [12, 120], although the exact mechanism of 
promoting cell migration and proliferation in the intimal layer remains controversial [127]. The 
hemodynamic disruptions caused by compliance mismatch also promote thrombosis [123]. 
Foreign material may exacerbate neointimal hyperplasia and thrombosis by paracrine effects 
from the chronic inflammation associated with long-lasting material, which promote migratory 
phenotypes in SMCs associated with neointimal hyperplasia, and activate endothelial cells 
toward a pro-coagulatory state [128]. Long-lasting materials also limit the potential for prosthetic 
vascular grafts to develop a thrombosis-resistant endothelium, as endothelial cells can only 
migrate 2 cm onto foreign material from adjacent arteries in humans, thereby leaving the 
majority of vascular graft length without a confluent endothelium [129]. Infection risk is also 
substantially exacerbated by long-lasting materials, which are known to serve as a nidus for 
microbial colonization and subsequent biofilm formation [130]. 
 A fast-remodeling bio-inductive graft could avoid these late-term failures by minimizing 
the duration of the host’s exposure to foreign materials. However, an additional late term risk in 
fast-remodeling grafts is aneurysmal dilatation, which can occur if the loss of graft strength due 
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to degradation exceeds the rate at which developing neotissue can bear load. Aneurysmal 
dilatation is seen in rarely-used homografts and heterografts, and can cause catastrophic failure 
by rupture, as well as thrombosis and/or embolism due to endothelial disruption associated with 
aneurysm pathology [131]. A fast-remodeling bio-inductive vascular graft must avoid 
aneurysmal dilatation as well as traditional late-term failure modes to improve graft performance 
compared to prosthetic conduits.  
In this chapter, we examined the long-term in vivo stability of microporous composite 
fast-remodeling grafts. This evaluation is essential for understanding the design’s potential for 
translation, as vascular grafts must conduct blood flow for the remainder of the patient’s lifetime. 
We hypothesized that at late-term, neoarteries will maintain homeostasis without complication, 
as material residues are largely absent at 3 months and the neotissue is elastin-rich and 
compliant. To test this hypothesis, we implanted composite grafts into rats as abdominal aorta 
interpositions, and incubated for 1 year. At term, we characterized neoarteries extensively both in 
vivo and ex vivo, and compared with age-matched unoperated controls. 
2.2 METHODS 
2.2.1 Fabrication of composite vascular grafts 
SCPL PGS-PCL grafts were fabricated as previously described [118]. Briefly, PGS prepolymer 
was synthesized in house [132]. The PGS core of the composite graft was fabricated by casting a 
PGS prepolymer solution into a fused salt template within a tubular mold. To cross-link the PGS 
prepolymer, constructs were heat cured at 150 °C under vacuum for 24 h to produce a PGS-salt 
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template. To fabricate the PCL sheath, PCL (Mn 80 kDa; Aldrich, St. Louis, MO) was dissolved 
in 2,2,2-trifluoroethanol at 14% weight/volume and electrospun onto a rotating PGS-salt 
template at 20 RPM. Salt was removed from PGS-PCL-salt composites by immersing them in 
deionized water. Composite grafts were lyophilized (Labconco Freezone 4.5, Kansas City, MO) 
and stored in a desiccator at ambient temperature until use. Grafts were sterilized with ethylene 
oxide prior to implant. 
2.2.2 Implantation 
Rats were cared for in compliance with protocols approved by the Institutional Animal Care and 
Use Committee (IACUC) of the University of Pittsburgh following NIH guidelines for the care 
and use of laboratory animals (NIH publication No. 85–23 rev. 1985). We used male Lewis rats 
(body weight: 200–250 g, n = 5, Charles River Laboratories, Boston, MA) for experiments. We 
performed interpositional implantation in rat abdominal aortas as follows. Rats were anesthetized 
by isoflurane inhalation (5% for induction, then 2-3% for maintenance). A midline abdominal 
incision was made to expose the abdominal aorta. The aorta was separated from the inferior vena 
cava, the infrarenal abdominal aorta was cross-clamped, and then a 4-mm segment was 
transected. The SCPL PGS-PCL graft (8-10 mm long) was placed in the gap and connected to 
the native aorta by end-to-end anastomosis with 9-0 suture. Rats received no anticoagulation or 
antiplatelet treatment preoperatively or postoperatively. After implantation, grafts resorbed and 
transformed into “neoarteries” (regenerated arteries). At one year post-implant, neoarteries were 
characterized in situ, then rats were sacrificed to explant grafts for ex-vivo analysis (n = 5). 
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2.2.3 In vivo dynamic mechanical compliance 
In a non-survival surgery, rats were anesthetized with isoflurane inhalation (5% for induction, 
then 2-3% for maintenance), then ventilated by the insertion of a tracheal cannula attached to a 
rodent ventilator (Harvard Apparatus, South Natick, MA) set to 90 breaths/min with a tidal 
volume of 8 ml/kg body weight. The chest was opened with a midline incision and then a four-
electrode pressure-volume catheter (Scisence Inc., London, Ontario, Canada) was placed through 
the left ventricular apex and fed into the aortic arch. aortic pressure and neoartery inner diameter 
were measured simultaneously to determine the dynamic mechanical compliance of neoarteries. 
Aortic pressure was measured using the same pressure-volume catheter used in arterial 
impedance measurement. To measure neoartery inner diameter, hair was removed from the 
abdominal skin, then the abdominal aorta was imaged transcutaneously using a 21 MHz 
ultrasound linear probe (MS 250) connected to a high frequency small animal imaging system 
(Vevo2100, Visualsonics, Canada) in B-scan mode. The change in inner diameter of neoarteries 
due to blood pressure was measured from B-scan images. Dynamic mechanical compliance was 
calculated from Equation 1:  
C = ((Dinner(PSystole) - Dinner (PDiastole)) / (Dinner(PDiastole)) × 100) / (PSystole - PDiastole) (1) 
where Dinner represents inner diameter, PSystole represents aortic pressure at systole, and PDiastole 
represents aortic pressure at diastole. 
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2.2.4 Characterization of neoartery vasoactive properties 
The following were obtained from Sigma-Aldrich, St. Louis, MO: L-phenylephrine 
hydrochloride, norepinephrine, acetylcholine chloride, sodium nitroprusside dihydrate, serotonin, 
and forskolin. Animals were humanely euthanized. Functional arterial myography assays were 
performed as previously published with several modifications. [133] The neoarteries or native 
aortas were dissected free, cleaned of surrounding connective tissue, and placed in standard 
Krebs buffer (composition in mM: NaCl, 118.4; KCl, 4.7; CaCl2, 2.5; MgSO4, 1.2; KH2PO4, 
1.2; NaHCO3, 25; dextrose, 11.1; Na2Ca EDTA, 0.029; pH 7.4). Aorta segments (2 mm in 
length) were mounted in a dual wire myograph system (Multiple Myograph Model 610 M, DMT, 
Denmark). The rings were allowed to equilibrate in Krebs buffer with 95% O2 - 5% CO2 at 37 
ºC at the optimized passive tension. Single dose challenges to phenylephrine (PE) and serotonin 
(5-HT) were performed. Rings were then preconstricted to serotonin (5-HT) and allowed to reach 
a steady-state plateau. Single dose challenges to acetylcholine (Ach) and forskolin were then 
determined. In other experiments log-dose response curves of preconstricted rings to the NO 
prodrug sodium nitroprusside (SNP) were obtained. Concentration-response curves were plotted 
as percentage of relaxation using all points on the concentration-response curve by nonlinear 
regression curve fitting using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). Data 
represents results from 12 individual neoartery ring assays, derived from explants from 3 
animals.  
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2.2.5 Histology and immunofluorescence 
All microscope images presented are representative fields from at least three different animals. 
Neoartery images are all taken from the middle 4 mm of the remodeled graft. Explants were 
fixed in 2% paraformaldehyde (Electronic Microscopy Sciences, Hatfield, PA) for 2 h at room 
temperature, then frozen in Optimal Cutting Temperature Compound (OCT; Tissue-Tek, 
Torrance, CA) with liquid nitrogen and stored at -80°C until use. Sections were cut to 8 µm 
thickness using a cryomicrotome (HM525, Thermo Scientific, Waltham MA), mounted on glass 
slides, and stored at -80°C until staining. Slides were stained with hematoxalin and eosin (H&E), 
Picosirius red, and von Kossa according to standard protocols, and imaged using a Nikon Eclipse 
Ti inverted microscope with Nikon Elements software (Melville, NY). Slides stained with 
Picosirius red were illuminated with plane-polarized light and imaged using differential 
interference contrast (DIC). Immunofluorescent staining was performed as follows: slides were 
incubated in 5% normal goat serum (Sigma, St. Lois, MO) for 1 h at 37 °C, incubated with 
primary antibodies in 1% goat serum for 45 min at 37 °C, rinsed with Phosphate Buffered Saline 
(PBS; Mediatech, Manassas, VA), and incubated with secondary antibodies in 1% goat serum for 
45 min at 37 °C. Primary antibodies are listed in Table 2. Secondary antibodies included goat 
anti-mouse or goat anti-rabbit AlexaFluor 594 (1:400; Invitrogen, Grand Island, NY). Slides 
were coverslipped in VectaShield Hard Set mounting medium with DAPI (Vector Laboratories, 
Burlingame, CA), which co-stains nuclei blue. Coverslipped slides were stored at 4°C protected 
from light until being imaged with a Nikon Eclipse Ti inverted microscope. 
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Table 2. Primary antibodies for immunofluorescence microscopy 
Antigen Host Dilution Manufacturer Location Product no. 
α-smooth muscle actin (αSMA), FITC 
conjugated Mouse 1:1000 Sigma St. Louis, MO F3777 
von Willebrand Factor (vWF) Rabbit 1:400 Abcam Cambridge, MA Ab6994 
CD68 Mouse 1:250 Millipore Billerica, MA MAB1435 
Elastin Rabbit 1:100 Abcam Cambridge, MA Ab21610 
Fibrillin-1 Rabbit 1:100 Santa-Cruz Dallas, TX Sc20084 
Collagen III Rabbit 1:100 Abcam Cambridge, MA Ab7778 
Collagen I Rabbit 1:40 Millipore Billerica, MA Ab745 
 
 
 
2.2.6 En face immunofluorescence microscopy 
Neoartery explants were cut into 1 to 2 mm long rings, then cut longitudinally into segments. 
Segments were fixed in 2% paraformaldehyde for 2 h at room temperature. Segments were then 
immunostained as whole mounts by blocking in 2% bovine serum albumin (BSA; EMD 
Chemicals, Gibbstown, NJ) with 0.1% Triton-X100 (Sigma) for 6 h at 4 °C, incubating in 
primary antibodies overnight at 4 °C, washing with 0.5% BSA for 5 h at 4 °C, incubating in 
secondary antibodies overnight at 4 °C, then rinsing again with 0.5% BSA. Segments were 
stained for either (1) endothelial cells, or (2) perivascular nerves. For endothelial cell staining, 
primary and secondary antibodies were mouse anti-rat CD31 (1:250; Millipore MAB1393) and 
goat anti-mouse AlexaFluor 594 (1:200; Invitrogen), respectively. For nerve staining, segments 
were co-stained with two primary antibodies: rabbit anti-rat protein gene product 9.5 (PGP 9.5; 
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1:250, Millipore Ab9724) and mouse anti-rat β-Tubulin (1:1000; Sigma T5293). Secondary 
antibodies were goat anti-rabbit AlexaFluor 594 (1:200; Invitrogen) and goat anti-mouse 
AlexaFluor 488 (1:200; Invitrogen), respectively. Dual staining was used to reduce effects of 
nonspecific staining which are amplified in whole mount imaging. To prepare stained whole 
mounts for imaging, segments were mounted in gelvatol on glass slides, flattened under a 
coverslip, and stored at 4 °C protected from light until imaging. Glass slides were imaged en face 
using an Olympus Fluoview 1000 confocal microscope (Center Valley, PA), and Z-stacked 
images were flattened using MetaMorph imaging software (Molecular Devices, Downingtown 
PA). 
2.2.7 En face multiphoton microscopy 
Neoartery explants were cut, fixed, and mounted as done for en face immunofluorescence, but 
without incubation in BSA or antibodies, and saline was used instead of gelvatol for mounting. 
Collagen and elastin autofluorescence within the neoartery wall was measured as previously 
described using an Olympus Fluoview FV1000-MPE Multiphoton microscope with a 1.12 NA 
25x MPE water immersion objective [134].  Excitation was set to 870 nm, and the emission 
range was set to 400-500 nm and 525-575 nm for collagen and elastin, respectively. To image 
collagen and elastin close to the abluminal (outer) surface, explants were placed within the wells 
of hanging drop slides, coverslipped, and turned with the abluminal surface facing the objective. 
A schematic depicting each en face view is shown in Figure 7. 
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2.2.8 Elastin quantification 
Neoartery explants were cut into ring segments as described for en face imaging. Each segment 
was minced finely, weighed to obtain wet weight, and then digested three times with 0.25 M 
oxalic acid at 95 °C for 1 h to extract mature insoluble elastin into the solution supernatant. 
Elastin content in each extract was measured using a Fastin Elastin assay (F2000; Biocolor, 
Carrickfergus, UK) according to manufacturer’s instructions, then pooled and normalized to 
sample wet weight to yield the mass of insoluble elastin per tissue wet weight (µg/mg). Sample 
size: n = 3 for neoarteries and native aortas. All samples were tested in duplicate during the same 
assay run, except for one neoartery for which there was insufficient tissue to run in duplicate. 
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Figure 7. Schematic of en face multiphoton microscopy 
En face imaging of collagen and elastin autofluorescence using multiphoton microscopy. A. View of the explanted 
“neoartery” (regenerated artery) near the luminal surface. The middle of each neoartery was cut into ring segments, 
then cut open into ring halves and flattened between a glass slide and a cover slip. Slides were imaged with the 
luminal surface facing the objective. Neoarteries were imaged within 10 µm of the luminal surface. B. View of the 
media-like layer of the neoartery. Explants were mounted as in A, then the viewing plane was focused within the 
vessel wall, at least 10 µm from the luminal surface. C. View of the adventitial surface of the neoartery. Mid-graft 
segments were cut into ring halves as in A, then placed in hanging drop glass slides which contain a cavity within 
the slide. Slides were coverslipped and imaged with the adventitial surface facing the objective. Image from [135]. 
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2.2.9 Statistical Analysis 
Comparisons between two groups were made with a two-tailed Student’s t-test using IBM SPSS 
Statistics 19 software (Armonk, NY). Comparisons between three groups were made using a 
one-way analysis of variance test followed by Tukey’s Honestly Significant Difference (HSD) 
post hoc test using GraphPad Software (LaJolla, CA). 
2.3 RESULTS 
2.3.1 SCPL PGS-PCL grafts remodel into “neoarteries” resembling native arteries 
By one year post-implant, SCPL PGS-PCL grafts transformed into tissues grossly resembling 
native aortas (Figure 8) with similar tissue architecture and no visible graft material residues 
(Figure 9).  “Neoarteries” (regenerated arteries) showed a confluent endothelium as 
demonstrated by complete coverage of the luminal surface with cells positive for von Willebrand 
Factor (vWF) and CD31 (Figure 10).  Endothelial cells in neoarteries had cobblestone-like 
morphology and alignment in the direction of blood flow, as seen in native aortas (Figure 10 B). 
The middle layer of the neoartery vascular wall contains many smooth muscle-like cells with 
elongated nuclei which stain positively for α-SMA, resembling the native arterial medial layer 
(Figure 10 A). Many α-SMA+ cells are also positive for myosin heavy chain 11 (MHC-11), 
suggesting a mature, contractile phenotype (Figure 10 C). Some α-SMA+ cells are negative for 
MHC-11, suggesting they are myofibroblasts or smooth muscle cells of a synthetic phenotype.  
Regenerated arteries showed an adventitia-like layer outer layer of less dense, α-SMA-negative 
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tissue which stains positive for DAPI. Interestingly, neoarteries contain some cells which are 
negative for α-SMA and MHC-11 in the vascular media-like layer, including cells with 
elongated nuclei. In sparse, unrepresentative sections of neoarteries, the majority of cells in the 
media-like vascular layer are negative for smooth muscle markers (Figure 11). These cells have 
yet to be identified. Neoarteries also contain some α-SMA and MHC-11 positive cells adjacent to 
the endothelium which are not elongated in the circumferential direction (Figure 10 and Figure 
11).  
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Figure 8. Gross morphology of neoarteries. 
A. Left: transformation of SCPL PGS-PCL graft into neoartery in situ over the course of 1 year. Nondegradable 
sutures (black) mark the graft location. Right: Transverse view of explanted neoarteries resembles that of native 
aortas. B. Longitudinal view of explanted neoarteries resembles the adjacent native aorta. All ruler ticks are 1 mm. 
Image from [135]. 
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Figure 9. Hematoxylin and eosin staining of neoarteries 
H&E stained transverse sections of the middle of neoarteries show similar tissue architecture with native aortas, with 
no sign of residual graft material. Scale bar 100 µm. Image from [135]. 
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Figure 10. Vascular cell phenotypes within neoarteries. 
A. Neoartery sections immunostained for von Willebrand factor (vwf, red) and alpha smooth muscle actin (α-SMA, 
green). The luminal surface of neoarteries is completely covered by vWF positive cells (red), suggesting a confluent 
endothelium. Neoarteries contain a media-like middle layer of the vascular wall rich in α-SMA positive cells with 
circumferentially elongated nuclei, similar to vascular smooth muscle found in native aortas. The outermost layer of 
neoarteries lacks α-SMA, resembling native adventitia. Some cells in the media-like layer are negative for α-SMA, 
and some cells adjacent to the endothelium are α-SMA positive but not circumferentially elongated. Scale bar 100 
mm. L indicates vessel lumen. Nuclei stained with DAPI (blue). B. Immunostaining for smooth muscle myosin 
heavy chain 11 (MHC-11, red). Many elongated cells in the media-like layer are positive for MHC-11, suggesting a 
mature, contractile smooth muscle phenotype. The distribution of MHC-11 appears similar to that of α-SMA. MHC-
11 positive cells in neoarteries stain brighter than those in native aortas at the same exposure. Scale bar 100 mm. L 
indicates vessel lumen. Nuclei stained with DAPI (blue). Image from [135]. 
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Figure 11.  Some neoartery media cells negative SMC markers. 
Unrepresentative transverse section of neoartery differs from native arteries in cell phenotypes. Left: H&E stained 
neoartery. Right: Serial neoartery section immunostained for vWF (red) and α-SMA (green). The majority of cells 
within the vessel wall are negative for α-SMA, including cells with elongated nuclei which look similar to smooth 
muscle cells in H&E stained sections (arrow outlines). Many cells adjacent to the endothelium are positive for α-
SMA, but exhibit punctate morphology rather than alignment in the circumferential direction (solid arrows). Scale 
bar 100 µm. Image from [135]. 
 
2.3.2 Neoarteries resist common modes of late-term vascular graft failure 
One-year patency was unchanged from the three-month patency of 80% [118], suggesting 
resistance to late-term failure. The only occluded SCPL PGS-PCL graft was likely closed by 
acute thrombosis, as the non-vascular tissue architecture at the mid-graft suggests little 
constructive remodeling occurred before occlusion, and the tissue occluding the graft lumen does 
not resemble neointimal hyperplasia (Figure 12). Patent grafts showed no statistically significant 
difference in inner diameter compared with native arteries, suggesting resistance to both dilation 
and narrowing by neointimal hyperplasia (Figure 13 A). Neoarteries showed no evidence of 
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mineralization or calcification, as they are negative for von Kossa staining (Figure 13 B). 
Macrophages are present only in the adventitia-like region of regenerated arteries at 1 year post-
implant, likely associated with a small amount of remnant PCL (Figure 13 C). 
 
 
 
 
Figure 12.  Occluded SCPL PGS-PCL graft at 1 year post-implant. 
Occluded graft at 1 year post-implant. Left: H&E of transverse section of middle of occluded graft. Scale bar 250 
µm. Right: Occluded graft at the suture line. Bottom: Boxed region of occluded graft at suture line. The non-vascular 
tissue architecture suggests occlusion soon after implantation, as little constructive remodeling occurred before 
occlusion. The tissue occluding the graft lumen is densely cellular but does not resemble neointimal hyperplasia, 
suggesting thrombosis as a likely cause of occlusion. White arrow outlines depict vascular media from the native 
aorta proximal to the graft. Black arrows denote suture. Scale bar 250 µm. Image from [135]. 
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Figure 13.  Neoarteries resist common modes of late-term graft failure. 
A. Neoartery inner diameter is not significantly different from that of age-matched native aortas, suggesting 
resistance to dilation and neointimal hyperplasia. B. Neoarteries are negative for von Kossa staining (black indicates 
a positive stain), suggesting resistance to calcification. Bone (rabbit ulna) was stained with von Kossa as a positive 
control for calcified tissue. Scale bar 500 µm.  C. Neoarteries contain cells positive for macrophage marker CD68, 
concentrated mostly in the outermost layer of the neoartery wall. Scale bar 100 µm. Image from [135]. 
 
2.3.3 Nerves in the perivascular space of neoarteries 
We searched regenerated vessels for perivascular nerves to (1) investigate whether neoartery 
tone could be regulated by the nervous system, and (2) determine whether nerves can regenerate 
and traverse the implant site. We found nerves on the adventitial surface of neoarteries with 
similar morphology and distribution to those found in native arteries (Figure 14). Nerves were 
positive for protein gene product 9.5, a nerve-specific marker commonly used to identify 
perivascular nerves. 
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Figure 14.  Perivascular nerves innervate neoarteries. 
A. Schematic of En Face imaging of the adventitial surface of neoarteries. Neoarteries were cut open, 
immunostained for protein gene product 9.5 (PGP 9.5) and β-Tubulin, and imaged as whole mounts using confocal 
microscopy with z-stack flattening. B. Perivascular nerves cover the adventitial surface of neoarteries with similar 
morphology to those in native aortas. Nerves appear yellow from the overlap of nerve-specific marker PGP 9.5 and 
nerve non-specific marker β-Tubulin, which stains nerves brightly but is also expressed ubiquitously. The co-
staining technique was used to reduce effects of nonspecific staining which are amplified in whole mount imaging. 
Scale bar 100 µm. Image from [135]. 
 
 
 
2.3.4 Neoartery extracellular matrix composition and mechanical properties 
Proper matrix composition and structure is crucial for the long-term mechanical stability of 
arteries. Excitingly, we found that regenerated arteries contain the same quantity of cross-linked 
elastin as found in native arteries (P = 0.80; Figure 15 A). Furthermore, neoarteries contain 
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fibrillin-1, a crucial component of functional elastic fibers (Figure 15 B). However, elastin and 
fibrillin-1 are less uniformly distributed in the media-like layer of neoarteries than in native 
aortas. Regenerated arteries contain collagens III and I as well, both found in native aortas, but 
their organization also differs from native aortas (Figure 16). These differences in matrix 
organization may be responsible for the apparent reduced dynamic mechanical compliance of 
neoarteries compared with native aortas (Figure 16 C). Although the difference was not 
statistically significant at the limited sample size (n = 4), the data appears to be trending toward 
significance. 
 
 
 
 
 
Figure 15.  Elastin content and organization in neoarteries. 
A. Elastin quantification using a Fastin Elastin assay showed that neoarteries contain the same amount of cross-
linked elastin per tissue wet weight as native aortas. B. Transverse immunostained cross-sections show that 
neoarteries contain both elastin and fibrillin-1, though the distribution differs from that of native arteries. L indicates 
vessel lumen. Scale bar 100 µm C. En Face view of the middle layer of the neoartery wall shows elastin 
autofluorescence (false-colored as green). Elastin is aligned perpendicular to the direction of blood flow (arrow), 
similar to native arteries Scale bar 25 µm. Detailed depiction of en face view shown in Figure 7. Transverse 
immunostained cross-sections of neoarteries show the distribution of collagen III and collagen I throughout the 
neoartery wall. Neoartery collagen III appears ubiquitously distributed, whereas collagen III localizes to vascular 
media in native arteries. Collagen I is less bright in neoartery adventitia compared with adventitia in native aortas. L 
indicates vessel lumen. Scale bar 100 µm. Image from [135]. 
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Figure 16.  Collagen content and mechanical properties of neoarteries. 
A. Transverse immunostained cross-sections of neoarteries show the distribution of collagen III and collagen I 
throughout the neoartery wall. Neoartery collagen III appears ubiquitously distributed, whereas collagen III localizes 
to vascular media in native arteries. Collagen I is less bright in neoartery adventitia compared with adventitia in 
native aortas. L indicates vessel lumen. Scale bar 100 µm. B. En Face view of the middle layer of the neoartery wall 
shows collagen autofluorescence (false-colored as red). Collagen in neoarteries shows some alignment perpendicular 
to the direction of blood flow (arrow), though it is less aligned and less crimped than collagen from native aortas. 
Scale bar 25 µm. Detailed depiction of en face view shown in Figure 7. C. In vivo dynamic mechanical compliance 
of neoarteries and native aortas. Neoarteries appear less compliant than native aortas, but the difference was not 
statistically significant in this limited data set (n = 4). Compliance was measured in vivo using ultrasound to record 
neoartery inner diameter and a manometer implanted in the aorta to record pressure. Compliance was taken as % 
change in diameter normalized to the difference between systolic and diastolic pressure. Image from [135]. 
 
 
 
2.3.5 En face comparison of elastin and collagen architecture 
Elastin in neoarteries was arranged as a fine fibrous network, in contrast to the fenestrated 
lamellae seen in native aortas (Figure 17 A, B). Near the abluminal surface, elastin is largely 
absent in neoarteries, similar to native adventitial matrix (Figure 17C).  Throughout the majority 
of the neoartery wall, collagen was aligned in the circumferential direction similar to native 
medial collagen (Figure 18). However, regenerated collagen lacked the crimped fibril 
morphology seen in native aortas and showed weaker fiber alignment. Interestingly, the axis of 
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collagen alignment changed near the luminal surface in some regions of neoarteries (Figure 18, 
region 2). Collagen near the albumen is crimped resembling native adventitial collagen, but 
crimp is still less than in native arteries, and neoartery collagen is aligned more strongly than that 
of the native adventitia (Figure 18, right).  
 
 
 
 
Figure 17.  Elastin architecture in neoarteries and native aortas. 
Detailed depiction of en face view shown in Figure 7. Scale bars 25 µm. A. Elastin architecture within the neoartery 
wall, imaged > 10 µm from the luminal surface (left), or within 10 µm of the lumen (right). Elastin is arranged as a 
fibrous network in neoarteries, in contrast to the fenestrated lamellae seen in native aortas. “Fe” indicates 
fenestrations in elastic lamellae in native aortas. “Fold” notes where the lamellae drop below the viewing plane. B. 
Schematic of the elastic lamella of native arteries. C. Elastin architecture near the abluminal surface of neoarteries. 
Neoarteries contain little elastin near the abluminal surface, similar to native aortas. Image from [135]. 
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Figure 18.  Collagen architecture in neoarteries and native aortas. 
Detailed depiction of en face view shown in Figure 7. Scale bars 25 µm. Collagen architecture within the neoartery 
wall, viewed from the luminal side. Collagen is less aligned and less crimped than collagen seen in native aortas. 
Two regions from the same vessel segment (Region 1 and Region 2) are shown to demonstrate variation in collagen 
architecture within the same neoartery. Regions 1 and 2 represent different circumferential locations at the same 
longitudinal position near the middle of the regenerated vessel. In both regions, collagen at >10 mm from the 
luminal surface is oriented in the circumferential direction, as seen in the vascular media of native aortas. However, 
collagen at <10 mm from the lumen can either retain its orientation (Region 1) or substantially shift its orientation 
(Region 2), the latter contrasting with collagen near the intima of healthy native aortas. Arrows indicate the 
circumferential direction (white) and direction of orientation (blue). Right: Collagen and architecture near the 
abluminal surface of neoarteries is undulated resembling native adventitial collagen, but has higher undulation 
frequency than native arteries. Neoartery collagen alignment is stronger than that in native adventitia. Image from 
[135]. 
 
 45 
2.3.6 Neoartery response to physiologic vasodilators and vasoconstrictors 
We used standard dual pin wire myography to determine whether neoarteries could respond to 
vasomotor signals. Neoarteries constricted in response to both the selective α1-adrenergic 
receptor agonist phenylephrine (PE) and the 5-hydroxytryptamine receptor activator serotonin 
(5-HT), though the magnitude of constriction was significantly less than that of native aortas 
(32.5 +/- 2.78 vs. 1616 +/- 836.6 mg and 42.2 +/- 25.8 vs. 3485 +/- 1161 mg for PE and 5-HT, 
respectively) (Figure 19 A). Regenerated vessels displayed vasodilation to the endothelial-
specific activator acetylcholine (Ach) (Figure 19 B), suggesting the presence of signaling 
capability between endothelial cells and contractile smooth muscle. Percent relaxation in 
response to Ach was significantly larger than observed in native arteries. Neoarteries also dilated 
in response to endothelium-independent vasodilators including the andenylyl cyclase activator 
forskolin (Figure 19 C) and the direct soluble guanylyl cyclase (sGC) activator sodium 
nitroprusside (SNP) (Figure 19 D), though magnitude differed from native aortas. However, due 
to small sample size we cannot completely rule out the potential for passive relaxation to 
contribute to our observed results. Nonetheless, regenerated vessels showed no substantial 
dilation in situ at the time of explant, suggesting the absence of passive relaxation in vivo. Taken 
together these data demonstrate that the neoarteries are sensitive to several physiologically 
relevant activators and can translate these signals into vasoactivity, suggesting that some 
vascular cells within neoarteries express healthy phenotypes. 
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Figure 19. Response to vasodilators and vasoconstrictors. 
Neoarteries display sensitivity to vasodilators and vasoconstrictors. A. Response to physiologic vasoconstrictors. 
Neoarteries were freshly harvested, mounted on a standard dual pin myograph, resting tension established, then 
assessed in their response to vasoconstrictors. Neoarteries demonstrated constriction in response to both the selective 
a1-adrenergic receptor agonist phenylephrine (PE) and the 5-hydroxytryptamine receptor activator serotonin (5-HT). 
However, the magnitude of constriction was substantially less than native arteries (32.5 ± 2.78 vs. 1616 ± 836.6 mg 
and 42.2 ± 25.8 vs. 3485 ± 1161 mg for PE and 5-HT, respectively). Results are the mean ± standard error of the 
mean of n = 12 rings from 3 animals per treatment group. *P > 0.05. B-D. Response to physiologic vasodilators. 
Neoarteries were mounted as described in A, preconstricted with serotonin, then assessed in their response to 
vasodilators. Results are the mean ± SEM of n = 12 rings from 3 animals per treatment group. *P < 0.05. B. 
Neoarteries relax in response to the endothelial-specific activator acetylcholine (Ach, 10 mM), suggesting signaling 
capability between endothelial cells and contractile smooth muscle. C. Neoarteries relax in response to the cAMP 
activator (NO independent) forskolin (10 mM). D. Neoarteries respond to the vascular smooth muscle cell specific 
activator sodium nitroprusside (SNP) in a dose-dependent manner. 
2.4 DISCUSSION 
An ideal vascular graft should conduct blood flow for the duration of a patient’s lifetime. 
Consequently, long-term in vivo performance is an important indicator of a new vascular graft’s 
clinical potential. A number of cell-free, bio-inductive vascular grafts have shown promising 
long-term results (> 3 months) in small animals. HYAFF-11 rat abdominal aorta grafts 
completely resorbed by 120 days and remodeled into artery-like tissues with elastic fibers [136]. 
Silk fibroin grafts showed good patency as rat abdominal aorta grafts, but some residual material 
and substantial inflammation were still present at 1 year post-implant [137]. PLA, PEUU, and 
PCL have also shown good long-term patency as rat abdominal aorta grafts, but graft resorption 
and cellular infiltration were limited due to slow material degradation [108, 111, 138].  
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Long-term assessments in large animals have shown variable results for acellular bio-
inductive vascular grafts. Early work employing cell-free PGA graft yielded impressive long-
term results in large animals. Bowald et al. showed that PGA-based grafts implanted as short 
aorta grafts in pigs remodeled into neoarteries with artery-like tissue architecture at up to 2 years 
post-implant [99]. Elastin was present in substantial quantity, although it was less organized than 
the native elastic lamina [92]. Greisler and colleagues investigated PGA-based grafts as well, and 
found that aorta grafts in rabbits formed similar neoarteries with moderate stability at up to 12 
months, though elastin was largely absent, and dilation and neointimal hyperplasia occurred in 
some grafts. Slower-degrading polydioxanone grafts resorbed within 6 months and reduced rates 
of aneurysmal dilatation, but also reduced the rate of tissue ingrowth [96]. Fast-resorbing 
polyurethanes with physiologic compliance were investigated for their capacity to generate 
neoarteries while avoiding compliance mismatch. Initial testing of polyurethane grafts as pig 
aorta grafts yielded good patency and neoartery formation with organized elastic fibers at up to 6 
months post-implant [97]. A similar polyurethane graft demonstrated high propensity for 
thrombosis, requiring aspirin to recover patency [98]. Canine carotid artery replacements made 
from small intestinal submucosa (SIS) showed similar patency to saphenous vein grafts at 1 year 
post-implant [104]. Composite grafts made from PGA, PLA, and collagen also performed well as 
canine carotid artery replacements for 1 year, but showed limited cell infiltration and graft 
resorption [107]. HYAFF-11 grafts in porcine carotid arteries showed complete graft resorption 
and remodeling into artery-like tissues with elastic fibers over the course of 5 months, though 
intimal hyperplasia and thrombosis was observed in some implants [139]. Decellularized tissue 
engineered blood vessels based on PGA showed good patency at 6 months as an arteriovenous 
shunt in baboons and at 1 year as a carotid artery replacement [53]. Devitalized tissue engineered 
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blood vessels made from fibrin and human dermal fibroblasts matched native artery compliance 
post-decellularization, and demonstrated complication-free remodeling into elastin-rich 
neoarteries in 24 weeks as ovine femoral interposition grafts [43]. 
Our design departs from the above by using a faster resorbing material which enables 
more rapid host remodeling. The vast majority of our SCPL PGS-PCL graft design is completely 
resorbed by 30 days post-implant, except for sparse PCL residues [118]. The advantage of this 
approach is that it minimizes the duration of host’s response to foreign material, which may 
promote neointimal hyperplasia [128], calcification [138, 140], and tissue regression [138] in the 
late term. Indeed, we found that our grafts showed no sign of tissue regression, no significant 
narrowing from neointimal hyperplasia, and resisted calcification at 1 year post-implant. Grafts 
also resisted dilation and aneurysm, common failure modes for resorbable synthetic and collagen 
based vascular grafts. The only graft occlusion appeared to be thrombosis. The time of 
thrombosis is unknown, but it likely occurred during or shortly after surgery, as we did not use 
systemic heparinization during graft implantation. Systemic heparinization is standard practice 
for human surgery, and should substantially reduce the risk of thrombosis in SCPL PGS-PCL 
grafts.  
In addition to displaying encouraging long-term patency, SCPL PGS-PCL grafts 
remodeled into neoarteries demonstrating close resemblance to native aortas at 1 year post-
implant. This design regenerated nerves in perivascular tissue, and neoartery responsiveness to 
some vasomotor agents suggests these nerves may regulate vascular tone. Two other groups have 
also demonstrated vasomotor responsiveness in cell-free degradable vascular grafts [106, 141]. 
SCPL PGS-PCL grafts achieve full regeneration of the amount of mature elastin seen in native 
tissue. Coupled with the graft’s stable inner diameter, this data demonstrates that neoarteries are 
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mechanically stable at late term despite complete or near-complete resorption of the original 
graft material.  
Understanding the graft remodeling process will empower the research community to 
reproduce or improve this favorable long-term performance in future graft designs. While 
developing a comprehensive understanding is beyond the scope of this dissertation, the data 
collected to date allows for some speculation. The acute host response to the graft (0 to 48 h 
post-implant) can be speculated from findings in the wound healing, foreign body response, and 
angiogenesis literature. Acute response should begin with protein adsorption on the biomaterial 
and the deposition of a fibrin-rich a “provisional matrix” within the graft wall [142]. Platelets 
and a range of myeloid cells are likely included in the provisional matrix within graft pores. 
Other early-responding cells include neutrophils, mast cells, and lymphocytes [142, 143]. During 
the acute response, platelets, provisional matrix thrombolytic agents, and early responding 
inflammatory cells secrete a milieu of bio-active agents which recruit and activate multiple cell 
types. Two key multifunctional proteins released would include TGF-β and PDGF, which recruit 
macrophages [143] as well as smooth muscle cells [144] and myofibroblasts [145]. 
Myofibroblasts are contractile synthetic cells derived from multiple origins which contract tissue 
and secrete extracellular matrix [146]. Synthetic smooth muscle cells are a functionally similar 
cell population which are further described by a propensity to migrate and proliferate in blood 
vessels, but their distinction from myofibroblasts remains controversial [147]. These two cell 
types are the likely source of extracellular matrix including tropoelastin within the forming 
neoartery [34, 148]. These cells could originate from circulating fibrocytes [149], surrounding 
connective tissue, the adventitia of the adjacent vena cava, or the adjacent native aortic wall 
[129]. VEGF also likely plays a role in recruiting endothelial cells [150], and is secreted by M1 
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phenotype macrophages and hypoxic cells from the initial cell infiltrate [143]. In addition to their 
paracrine roles, phagocytic cells play a key role in degrading graft material by secreting acid, 
lipases, and reactive oxygen species [142]. Circulating stem and progenitor cells from the blood 
might be captured in the initial infiltrate, or may home to the implant site in response to 
chemotactic factors. These cells likely promote further cell recruitment, proliferation, and 
survival through paracrine signaling [151], and protect recruited cells from oxidative stress 
[152]. They may also differentiate into vascular cells [153], but the frequency of differentiation 
in situ and duration of their retention remains controversial [154]. 
The net result of these interrelated processes is a highly cellular proto-neoartery at 14 
days post-implant (Figure 5). These proto-neoarteries are abundant in both alpha-SMA+ 
myofibroblasts and/or synthetic smooth muscle cells, as well as contractile smooth muscle cells 
positive for myosin heavy chain. The relative contribution of these cells from the blood, native 
adjacent arteries, and surrounding connective tissue is unknown in our system and beyond the 
scope of this dissertation. However, a study of a similar bio-inductive vascular graft implanted in 
the venous circulation suggests that in short interpositional grafts in rodent models, the principal 
source of neovessel cells is the adjacent native vessel [154]. Regardless of origin, the synthetic 
smooth muscle cells and myofibroblasts likely continue to produce matrix and remodel the 
matrix past the 3 month time point, as wall thickness and matrix organization differs at each time 
point up to 1 year.  
Neoarteries at 14 days post-implant contain macrophages of both the classically activated 
M1 phenotype (CD68+ CD163-) and alternatively activated M2 phenotype (CD68+ CD163+) 
(Figure 5). Both phenotypes likely play constructive roles in the formation of the neoartery. M1 
macrophages degrade graft material, recruit more macrophages by secreting monocyte  
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chemoattractant protein-1 (MCP-1) [142], and secrete VEGF [155] to recruit endothelial cells 
[156]. M2 macrophages secrete PDGF-BB [155] which recruits smooth muscle cells and mural 
cells [144, 157], as well as TGF-β [142] which promotes synthetic phenotypes in smooth muscle 
and myofibroblasts, thereby promoting matrix production [145]. However, both macrophage 
types also exhibit tissue destabilizing behaviors; M1 macrophages produce reactive oxygen 
species and release pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α [143], while the 
TGF-β released by M2 macrophages can promote vessel stenosis by promoting smooth muscle 
cell migration into the neointimal and subsequent proliferation [158]. M1 macrophages are 
generally considered to be more tissue-destabilizing, and much biocompatibility literature 
suggests that M1 macrophages should be quickly replaced with M2 macrophages to avoid a 
classical foreign body response [159]. However, recent work has challenged this theory. Hibino 
et al. found that bio-inductive venous grafts containing more M1 macrophages than M2 
demonstrated reduced rates of stenosis [158]. Similarly, Sussman et al. found that implants 
which shift infiltrating macrophages toward an M1 phenotype showed less fibrosis and more 
vascularization [160]. Our findings corroborate the findings of the latter two groups, as the 
macrophage population in our grafts increased in the ratio of M1 to M2 phenotypes between 14 
and 90 days, and we saw constructive neoartery formation rather than excessive matrix 
deposition and prolonged inflammation. Macrophage phenotype was not measured at 1 year 
post-implant, but such a measurement could further inform our understanding of the graft 
remodeling process. Taken together, these results suggest that in a remodeling bio-inductive 
vascular graft, M1 macrophages may be desirable at up to 90 days post-implant, and possibly 
beyond. 
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 Despite substantial constructive remodeling, neoarteries still differ from native arteries 
even at 1 year post-implant. Neoartery collagen fibers are less crimped than those of native 
aortas in the unloaded state, suggesting they may provide a larger contribution to neoartery 
stiffness than collagen does in native aortas at physiologic pressures. Indeed, the compliance of 
neoarteries trends toward significantly less than that of native aortas, which is expected for a 
vessel whose collagen bears tensile loads at lower pressures. Encouragingly, neoarteries did not 
significantly dilate despite their engagement of collagen at physiologic pressures, suggesting that 
neoartery elastin bears sufficient load to prevent collagen creep.  
Macrophages remain present in the adventitia at 1 year, likely due to trace amounts of 
residual PCL, as PCL nanofibers can persist longer than 18 months in vascular grafts [138]. 
Neoarteries showed no evidence of late-term failure, suggesting the macrophages are not 
adversely affecting graft performance. The role of these macrophages in tissue homeostasis 
depends on their phenotype, which was not examined at the 1 year time point. M1 and M2 
macrophages facilitate tissue remodeling, and both phenotypes exhibit behaviors which could 
adversely affect neoartery homeostasis. Encouragingly, we saw no sign of either calcification or 
vessel narrowing from neointimal hyperplasia, suggesting that macrophage levels are likely 
below the threshold for complicating tissue homeostasis. 
Neoarteries at 1 year post-implant still contain some α-SMA+ cells which are likely 
myofibroblasts or smooth muscle cells with synthetic phenotypes, neither of which are present in 
large numbers in healthy native arteries. The presence of both cell types indicates that neoarteries 
could continue to change in matrix content and cellular organization even at 1 year post-implant. 
However, it is also possible that the neoartery has reached homeostasis despite the presence of 
synthetic cells, as apoptosis and matrix degradation could match rates of proliferation and matrix 
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production. The neoartery wall appears to have shrunk in thickness between 3 months and 1 year 
post-implant, so it is unknown whether such homeostasis is reached at 1 year. Synthetic smooth 
muscle cells could cause vessel narrowing by migrating into the neointima and proliferating as 
seen in neointimal hyperplasia [147], but we saw no significant narrowing of the lumen at 1 year 
post-implant. Still, neointimal hyperplasia may remain a risk at even later time points.  
The magnitude of the neoartery’s response to vasoconstrictors is smaller than that of 
native arteries, which could be explained by neoarteries containing less contractile smooth 
muscle than native arteries. Indeed, some elongated cells in neoarteries do not express smooth 
muscle markers, and some MHC+ smooth muscle-like cells are not elongated in the 
circumferential direction. Endothelium-dependent vasodilation in response to acetylcholine was 
larger in neoarteries than in native aortas, which may also be explained by differences in cellular 
distribution; neoarteries likely contain a similar number of endothelial cells to native arteries, yet 
have less smooth muscle, suggesting an increased ratio of endothelial to smooth muscle cells 
compared to native aortas. Since acetylcholine-induced relaxation relies on endothelial cells to 
transduce the signal to smooth muscle cells, the relative strength of the relaxation signal should 
be proportional to that cell ratio, which is higher in neoarteries. While neoarteries do not 
precisely mimic native vasoresponsiveness, response to vasomotor agents serves minimal 
physiologic function in the aorta or any arteries for which vascular grafts are used as bypasses or 
replacements. Thus the reduced capacity of neoarteries to change their tone should not impair 
their long term performance as conduits for blood flow. Rather than assessing neoartery function, 
myography serves to assess the overall health of arterial cellular and structural components. In 
this context, the observed vasoresponsiveness of neoarteries suggests that they contain some 
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contractile smooth muscle cells and some endothelial cells capable of transducing vasomotor 
signals to the smooth muscle.  
 The disparity between neoarteries and native arteries is expected, as graft remodeling 
differs from natural artery development. In the embryo, primitive blood vessels remodel into 
arteries largely in response to changing hemodynamic forces over the course of development 
[161]. In contrast, these grafts are immediately exposed to adult hemodynamics. In this context, 
it is remarkable that cells in the neoarteries synthesized ECM proteins with composition 
resembling native aortas. While neoarteries differ from native arteries, these differences might 
not be clinically significant, as neoarteries matched native arteries mechanically and 
demonstrated good long-term performance in vivo.  
We initially hypothesized that 1-year neoarteries would retain similar cell phenotypes and 
tissue architecture compared with neoarteries observed at 3 months [118]. The rationale was that 
neoarteries seemed to have reached homeostasis at that time, as material residues are largely 
absent at 3 months and the neotissue is elastin-rich and compliant. Surprisingly, the present study 
demonstrates that between 3 months and 1 year, neoarteries increase in elastin content, decrease 
in wall thickness, and achieve responsiveness to physiologic vasoconstrictors and vasodilators. 
These results indicate that in-host remodeling of neoarteries continues between 3 months and 1 
year post-implant in healthy rodents. Encouragingly, we saw no evidence of aneurysmal 
dilatation or other late term pathologies, suggesting that short SCPL PGS-PCL grafts in a healthy 
host are mechanically and biologically stable by 3 months despite continued remodeling. The 
persistence of likely synthetic αSMA+ MHC-11- cells at 1 year post-implant suggests that 
neoarteries may continue to remodel even after 1 year, and thus should be observed at later time 
points to fully appreciate their long-term stability.  
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The remodeling process occurring in this chapter’s SCPL PGS-PCL composite grafts 
compares favorably with that seen in many other bio-inductive grafts, but is not entirely unique 
to this design. Other fast-resorbing bio-inductive grafts have demonstrated the eventual 
formation of an elastin-rich neoartery [92, 93, 97, 98, 110, 114, 136, 139]. This is consistent with 
our central hypothesis, which postulates that rapid resorption of graft material is the key 
requirement for constructive neotissue formation rather than the excessive matrix deposition and 
prolonged inflammation seen in slow-resorbing or nondegradable vascular grafts. The rationale 
for this hypothesis is that rapid material clearance minimizes the duration of the inflammatory 
response, thereby reducing the duration of local promotion of dense matrix production, cell 
recruitment, and release of toxic macrophage-derived oxidants and pro-inflammatory cytokines.  
Other characteristics of the SCPL PGS-PCL graft may have also modulated the host 
response, but likely to a lesser extent. The close mechanical matching between PGS and native 
arteries likely promoted elastin production as has been previously demonstrated in vitro [121], 
but elastin-rich neoarteries can still be formed in stiffer bio-inductive grafts made from fast-
resorbing poly(glycolic acid) [92, 93] and poly(lactic acids) [110]. Favorable biocompatibility of 
PGS degradation products might also promote constructive neotissue formation, as PGS 
degradation produces a less acidic local environment than poly(glycolic acid) and poly(lactic 
acid)-based materials [162]; but again, neoarteries can still form from such polymers. The 
distribution of proteins adsorbed to the graft upon implantation is undoubtedly important in 
modulating the initial host response, but it was not investigated in this study. 
The importance of pore size in bio-inductive vascular grafts remains controversial. While 
some reports identify pore size as critical determinant of neotissue formation and inflammation 
[110, 160, 163], others have achieved elastin-rich neoartery formation using completely 
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nonporous but fast-resorbing implants [113, 114, 139]. The role of pore size in a PGS-based bio-
inductive vascular graft is unknown, but Chapter 4 provides some insight, as the graft design 
used in that investigation has substantially smaller pores than SCPL PGS-PCL grafts.  
2.5 LIMITATIONS AND FUTURE WORK 
Future work will address this study’s limitations.  Without cell seeding, it may be challenging for 
bio-inductive grafts to endothelialize in humans. The rat model we used does not test graft 
endothelialization to a clinical standard, as rats have superior endothelialization capacity to large 
animals and humans [129, 164]. Large animal studies will provide better indication of this 
design’s clinical potential. The host must replace the graft with artery-like tissue quickly enough 
to prevent dilation, but many patients have reduced healing potential due to old age and disease. 
Localized delivery of bioactive reagents may be necessary to accelerate both endothelialization 
and graft remodeling to prevent graft failure. A thicker slow-resorbing sheath could also protect 
from mechanical failure, but may promote neointimal hyperplasia by increasing compliance 
mismatch and generating chronic inflammation. Conversely, macrophages persisting in the 
neoartery at 1 year post-implant might be avoided if the graft sheath was made from a material 
that resorbs faster than PCL, thereby reducing the sheath’s residence time in vivo. Such 
modification would come at an increased risk for mechanical failure if patients cannot generate 
neotissue quickly enough to bear load. Quantifying total collagen content and staining for 
additional collagen types and subtypes could improve our understanding of neoartery health and 
mechanical stability. Further study is needed to determine whether passive relaxation contributed 
to vasodilation observed in neoarteries during myography. 
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Mechanisms of graft remodeling need to be studied to inform strategies to further 
accelerate graft remodeling. The contribution of myeloid cells could be determined by 
implanting grafts in chimeric rodents whose marrow cells express green fluorescent protein 
(GFP) or other reporters. The contribution of cells from the adjacent aorta could be tested by 
anastomosing to the graft an aorta segment from a male syngeneic donor, and then implanting 
the composite into a female animal. This model enables infiltrating cells from the donor vessel to 
be tracked using fluorescence in situ hybridization (FISH) for the Y chromosome [154]. 
Monitoring the phenotype of these tracked cells will shed substantial light on the remodeling 
process. Assessing cell phenotypes during the acute periods of graft remodeling (e.g. the first 
few days) will be necessary to characterize the initial cellular infiltrate, which likely plays a 
major role in dictating the ultimate fate of the neoartery. Conversely, further characterizing cells 
at late term can inform speculations on neoartery long-term stability. Staining for markers of 
proliferation (Ki-67) and apoptosis (Caspase 3) would reveal what cell turnover occurs at 1 year 
post-implant.  
Local protein delivery could be a powerful tool with which to accelerate and improve 
graft remodeling. Our laboratory has previously developed a novel delivery system which can 
locally releases a range of heparin-binding proteins [165]. Localized release of PDGF-BB could 
accelerate the recruitment of matrix-producing smooth muscle cells and myofibroblasts to the 
bio-inductive graft [144, 157], and TGF-β could further promote matrix production including 
tropoelastin [145]. Local release of VEGF [156] or FGF-2 [166, 167] could accelerate 
endothelial cell recruitment for lining the graft lumen or forming vaso vasorum.  Local delivery 
of monocyte chemoattractant protein 1 (MCP-1) could enhance early recruitment of 
macrophages, which has been previously shown to accelerate neotissue formation in bio-
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inductive grafts in the venous circulation [69]. Releasing SDF-1α from grafts could recruit 
circulating mesenchymal stem/progenitor cells from the blood, which may promote neotissue 
formation via paracrine effects [151], oxidant scavenging [152], and differentiation into vascular 
cells [153]. Our laboratory recently demonstrated that modifying SCPL PGS grafts to release 
SDF-1α enhances their recruitment of mesenchymal progenitor cells from a flow loop in vitro 
[168]. 
2.6  CONCLUSIONS 
This study demonstrates that a fast-resorbing, cell-free bio-inductive vascular graft can remodel 
in situ into tissues with favorable long-term stability and likeness to healthy arteries. It also 
shows that a neoartery can sustainably bear physiologic loading conditions despite continued 
constructive remodeling for months after graft material is resorbed. Taken together, these results 
suggest that this design is a promising strategy for improving the performance of vascular grafts 
used in small arteries. Additionally, fast-remodeling elastic implants may be applicable to other 
regenerative applications, including wound dressings and soft tissue repair. 
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3.0  IMPROVING TRANSLATIONAL POTENTIAL IN BIO-INDUCTIVE GRAFTS 
Favorable long-term performance is a key requirement for a bio-inductive vascular graft to have 
translational potential, but it is not the sole requirement. Surgical handling, fabrication yield, and 
manufacturing feasibility are also required for potential clinical use. In chapter 3, we report our 
progress on improving these qualities in our bio-inductive graft design.  
3.1 INTRODUCTION 
A new technology must satisfy many criteria to reach the clinic.  Surgical handling must be 
excellent to minimize implantation-related complications and meet the usability requirements of 
clinicians.  Fabrication must also be amenable to clinical translation. Manufacturing costs must 
be low to maintain the margins required for a sustainable medical product.  The manufacturing 
process must also yield reproducible outcomes to ensure the level of quality required for 
regulatory approval.  Low costs, fast production, and reproducible outcomes also benefit early 
stage academic research employing laboratory-scale fabrication methods. Time-consuming 
fabrication methods hamper research progress.  Large variability in graft properties amplify the 
variability of in vivo results, which can increase the number of animals required to find 
significant trends. Thus for a bio-inductive vascular graft to translate, it must demonstrate 
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excellent surgical handling and be fabricated in manner that is fast, lo2 w-cost, reproducible, and 
amenable to large-scale manufacturing.  
The SCPL PGS-PCL grafts described in Chapter 2 do not yet meet the requirements for 
translation. Many limitations in translational potential can be traced to the current fabrication 
technique used. The foam-like microporous structure of SCPL PGS is produced using a 
technique known as solvent casting particulate leaching (SCPL). In SCPL, a polymer or 
prepolymer solution is cast into a template of fused porogen particles. The polymer is cross-
linked if necessary, then the porogen template is dissolved to leave interconnected pores in its 
place (Figure 20). At the time of our investigation, macroporous PGS scaffolds were limited to 
SCPL fabrication. Alternative methods such as thermally induced phase separation (TIPS) or 3D 
printing are impractical due to the low glass transition temperature of PGS prepolymer, which 
causes the polymer to flow and fibers fuse into a nonporous sheet [169]. 
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Figure 20.  Solvent casting particulate leaching (SCPL) 
Schematic depicting the SCPL process. From left to right: Porogen template is formed by packing water soluble 
particles (porogen) into a mold. Porogen fusion (not pictured) may be performed to attach adjacent porogens to one 
another. Fusion improves interconnectivity of pores realized at the end of the process. Solvent casting adds the 
prepolymer solution to the porogen template, filling the space between porogen particles. Crosslinking uses heat or 
other means to change the prepolymer into crosslinked polymer. Porogen leaching uses rinses in water to remove 
water soluble porogen, leaving pores in its place. The result is a porous, foam-like polymer scaffold (right). 
 
 
 
Microporous vascular grafts based on SCPL PGS foams are impractical for clinical 
applications requiring suture anchoring and/or tensile loading conditions, as they are prone to 
failure by tearing. Consequently, successful implantation requires gentle surgical handling 
characteristic of reconstructive microsurgery, which is impractical to apply to human vascular 
surgery for two reasons: (1) vascular surgery imparts substantial tensile loads on grafts during 
implantation, with the magnitude of load varying greatly between cases; and (2) vascular 
surgeons typically lack microsurgery training. Even in a laboratory setting, SCPL PGS-PCL 
grafts are challenging to implant. In our experience, these grafts fail most frequently by tearing 
during suturing of the second anastomosis, which requires additional surgery time to excise and 
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replace the graft. The level of surgical training required to consistently implant SCPL PGS-PCL 
grafts is substantial. While our team member with microsurgical training could implant with 
100% success after a brief surgery learning curve, our pediatric surgeon collaborator tore all of 
the SCPL PGS-PCL grafts during attempted implantation. 
 The process of SCPL fabrication is also impractical for clinical translation. There is no 
known manufacturing equivalent for SCPL fabrication. Developing a novel large-scale 
manufacturing process for SCPL would be challenging. Per batch of 5 usable SCPL PGS grafts, 
fabrication requires skilled manual labor for 9 out of 19 steps, totaling 14.5 hours of skilled 
manual labor and nearly 200 hours lead time. Low reproducibility is another limitation, as 
within-batch variability is unacceptably high for mass production. The yield of grafts acceptable 
for implant is as low as 25% for an experienced operator, necessitating large batch sizes and the 
corresponding increase in manual labor required. The most common defects are thin, tortuous 
gaps in the graft which have the same effect as a physical tear. These gaps occur due to caking of 
porogen particles during the formation of the porogen template. The incidence of gap defects is a 
function of scaffold thickness and length, making it nearly impossible to fabricate defect-free 
long and thick-walled grafts, which are required for large animal studies. 
Electrospinning fabrication is an attractive alternative to SCPL. Electrospinning is a 
process which uses electrical forces to draw a polymer solution into mirco- or nano-scale fibers 
([170] for review). Electrospinning has several notable advantages over SCPL: (1) electrospun 
polymer constructs are typically stronger than their SCPL counterparts [171]; (2) Electrospinning 
is a semi-automatable process, thereby reducing fabrication time and the duration of skilled labor 
required; and (3) Electrospinning is substantially more reproducible than SCPL, dramatically 
increasing yield and improving quality toward potentially meeting regulatory standards.  
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Electrospinning thermosets like PGS is challenging [172] for two reasons: (1) the insolubility of 
crosslinked PGS in organic solvents necessitates the use of the uncrosslinked PGS prepolymer 
(pPGS); and (2) pPGS has a glass transition temperature (Tg) below room temperature causing 
the polymer to flow and fibers fuse into a nonporous sheet. This fusion is exacerbated by the 
high temperature needed for thermal crosslinking [169]. Overcoming these challenges could 
enable PGS-based vascular grafts or other implants to realize the improvements in translational 
potential associated with electrospinning fabrication. 
To improve the translational potential of fast-remodeling bio-inductive vascular grafts, 
we sought to develop a novel fabrication method which yields strong grafts in a simple, rapid, 
low-cost, and reproducible manner. We hypothesized that fabricating the PGS core from 
electrospun microfibers will improve surgical handling, fabrication yield, and manufacturing 
feasibility. To overcome the challenges of electrospinning PGS, we blended PGS prepolymer 
with a range of other polymers (termed “carrier polymers”) to enable microfiber formation, then 
constructed novel microfibrous grafts and characterized their handling in vitro and in vivo. 
Herein we report novel patent-pending [173] fabrication strategies including retaining or 
removing the carrier polymer from cross-linked PGS fibers, as well as cross-linking with either 
heat or chemical cross-linkers. (Figure 21). We used data from pilot implantation studies to 
guide our experimental approach. Consequently, not every graft design was fully characterized. 
Table 3 summarizes the development and characterization of each graft design tested. To 
distinguish these grafts from other designs described in this dissertation, we abbreviate them as 
“Espun PGS.” 
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Figure 21.  Fabrication strategies for Espun PGS-based implants 
Schematic runs from top to bottom. Blend with carrier polymer – PGS prepolymer (pPGS) must be blended with a 
carrier polymer to be electrospun using standard equipment. We investigated polycaprolactone (PCL), poly(lactic-
co-glycolic acid) (PLGA), poly(ethylene terepthelate) (PET), and poly(vinyl alcohol) PVA as carrier polymers. 
Cross-linking and electrospinning - pPGS must be cross-linked (x-linked) into PGS to attain the favorable 
biocompatibility associated with PGS. pPGS could be cross-linked prior to electrospinning using chemical cross-
linker lysine triisocyanate (left path), or after electrospinning using thermal crosslinking (right path). Only carrier 
polymers with high melting points (PVA and PET) could maintain a microfibrous structure through thermal cross-
linking. The result of this step is microfibers of cross-linked PGS blended with carrier polymer (PGS-carrierIntact). 
Carrier Removal – We investigated removing the carrier polymer by rinsing with solvents which dissolve the carrier 
(orange). Water and ethanol washes were used for removing PVA. Tetrahydrofuran (THF) and HFIP were used to 
remove PLGA and PET, respectively. PGS does not dissolve in these solvents due to its cross-links. The result of 
this step is microfibers of cross-linked PGS in which the majority of carrier polymer is removed (PGS-carrierRemoved) 
Fibrous PCL sheath – We applied a fibrous PCL sheath onto select grafts by electrospinning directly onto the 
abluminal surface of salt-hardened, PGS-only grafts. Salt hardening (not pictured) is described in methods. In total, 
our fabrication methods produced microfibrous PGS-PCL composite grafts (right; PGS-carrierRemoved PCLSheath), 
microfibrous PGS grafts (middle; PGS-carrierRemoved), and microfibrous blended grafts of PGS and a carrier polymer 
(left; PGS-carrierIntact). 
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Table 3. Development and characterization of Espun PGS graft designs. 
 
 
Carrier 
Polymer 
Microfiber 
Formation 
Cross-
linking 
Carrier 
Removal 
Apply PCL 
sheath 
Mechanical 
Testing Implantation 
PCL Y N N N N N 
PLGA Y Y Y and N* Y and N** Y Y 
PET Y Y Y N N N 
PVA Y Y Y Y Y Y 
 
 
*PGS-PLGA blended grafts were either purified of PLGA (Y), or retained PLGA (N). 
**PGS-PLGA blended grafts were implanted without PCL sheaths. PGS-only grafts (purified of PLGA) were 
sheathed with PCL in some cases. 
 
3.2 METHODS 
3.2.1 Materials 
PGS prepolymer (pPGS) was synthesized in house as described in 2.2.1.  Polycaprolactone 
(PCL) was obtained from Sigma-Aldrich, PCL (Mn 80 kDa; Aldrich, St. Louis, MO).  
Poly(lactic co-glycolic acid) PLGA was obtained from Lakeshore Biomaterials (L:G ratio 75:25, 
Mw 105 kDa; Birmingham, AL). Poly(ethylene terepthelate) (PET) was generously provided by 
the University of Toledo (Inherent viscosity = 0.80). Poly(vinyl alcohol) (PVA) was generously 
provided by Soarus LLC (Arlington Heights, IL). 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) was 
purchased from Oakwood Products Inc. (West Columbia, SC). 2,2,2-trifluoroethanol (TFE) was 
purchased from Acros Organics (Belgium). 
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3.2.2 Electrospinning fabrication and cross-linking 
Nomenclature. All electrospun microfibrous grafts are abbreviated as “Espun (p)PGS-
CarrierSuperscript (PCLsheath)”, where parentheses indicate that the abbreviation may be omitted. 
The “p” indicates prepolymer (if that is the final form of PGS); “carrier” indicates either PCL, 
PET, PLGA, or PVA; “superscript” describes whether the carrier polymer is left intact or has 
been removed; and “PCLSheath” describes whether or not the graft includes a microfibrous PCL 
sheath. For example, Espun PGS-PLGARemoved PCLSheath would indicate a graft made from 
electrospun, cross-linked PGS fibers blended with PLGA, in which the PLGA was subsequently 
removed, and an electrospun PCL sheath was placed around the graft. 
Espun pPGS-PCLIntact sheets.  To fabricate sheets of Espun pPGS-PCLIntact microfibers, 
pPGS was mixed with PCL at a mass ratio of 2:1 pPGS:PCL, then dissolved in tetrahydrofuran 
(THF) at a total polymer concentration of 33% (w/v). The pPGS-PCL blend solution was infused 
into an electrospinning setup consisting of a 22 gauge syringe needle spinerette (cathode) and an 
aluminum plate coated in aluminum foil as the collector (anode). The solution was infused 
through the spinerette at 10 μL/h. Voltage sources were used to set the cathode and anode 
voltages to +12.5 kV and -12.5 kV, respectively. The distance between the spinerette and the 
collector was set to 26 cm. 
Espun PGS-PLGAIntact Grafts. To fabricate tubes of crosslinked PGS blended with PLGA 
fibers (Espun PGS-PLGA), pPGS was mixed with PLGA at a range of mass ratios, then 
dissolved in THF. 300 mM of Lithium Bromide (LiBr) was added to each blend to enhance 
solution conductivity. To optimize the mass ratio of pPGS:PLGA, mass ratios of 8:2, 7.5:2.5, and 
7:3 were compared in their capacity to resist fusion between formed fibers. The optimized mass 
ratio was determined to be 7:3, and this ratio was used in all subsequent experiments. To 
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crosslink the pPGS into PGS, lysine triisocyanate (LTI) was added to the solution at 29 mol% 
with respect to PGS monomer. LTI was applied under nitrogen gas in a dry box immediately 
prior to electrospinning. The electrospinning solution was then infused into an electrospinning 
setup consisting of a 22 gauge syringe needle spinerette (cathode), and an aluminum plate 
(anode), and a mandrel placed between the two (collector) (Figure 22). Microfibers initially 
deposit onto the anode, then draw from the anode onto the rotating mandrel. The solution was 
infused through the spinerette at 12.5 μL/min. Voltage sources were used to set the cathode and 
anode voltages to +11 kV and -11 kV, respectively. The distance between the spinerette and the 
anode was set to 17.5 cm. The distance between the rotating mandrel and the aluminum plate 
was constantly adapted manually to maximize fiber collection efficiency. The rotating mandrel 
was comprised of water soluble glucose, formed by melting glucose in a custom mold, to enable 
release of microfibers by dissolution of the rod in deionized water. The mandrel outer diameter 
was typically 1.2 cm, and it was rotated at 350 RPM. 
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Figure 22.  Fabricating Espun PGS-PLGAIntact microfiber tubes 
A precursor solution containing PGS prepolymer (pPGS), PLGA, chemical cross-linker lysine triisocyanate (LTI), 
and LiBr is infused into an electrospinning chamber. PGS-PLGA microfibers first travel from the needle cathode 
(+V) to deposit onto the aluminum plate anode (-V). Microfibers then draw from the aluminum plate anode onto a 
rotating glucose mandrel. Soaking in water (right) dissolves the mandrel to leave only a microfibrous tube made 
from a blend of PGS and PLGA (Espun PGS-PLGAIntact) microfibers. 
 
 
 
Espun PGS-PETIntact sheets. To fabricate sheets of Espun pPGS-PET microfibers, pPGS 
was mixed with PET at a mass ratio of 2:1 pPGS:PET, then dissolved in 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP) at a total polymer concentration of 23% (w/v). The pPGS-PET 
blend solution was infused into an electrospinning setup consisting of a 22 gauge syringe needle 
spinerette (cathode), a stainless steel razor blade as the anode, and a rotating aluminum mandrel 
as the collector (Similar to Figure 22, except for mandrel composition and anode shape. Fibers 
sheets are isolated from the mandrel using a razor blade and pulling with forceps, rather than 
soaking in water). The solution was infused through the spinerette at 19 μL/min. Voltage sources 
were used to set the cathode and anode voltages to +7.5 kV and -7 kV, respectively. The distance 
between the spinerette and the collector was set to 27 cm. The distance between the rotating 
mandrel and the aluminum plate was 13.3 cm. The mandrel outer diameter was 2.54 cm, and it 
was rotated at 210 RPM. Sheets of pPGS-PET microfibers were thermally crosslinked to form 
PGS-PET microfibers by heating under vacuum in incremental steps to minimize the potential 
 69 
for melting and fiber fusion; Fibers were initially heated at 70 °C, then the temperature was 
increased 10 °C every 7-12 hours, terminating after heating at 120 °C. 
Espun PGS-PVAIntact grafts.  Initial blends using PVA to form Espun PGS-PVA sheets 
were developed by Eric Jeffries, a colleague in our laboratory. The following methods are 
published in [169] and described in patent application [173].  Briefly, A 16% w/v solution was 
prepared by mixing pPGS and PVA at 55:45 mass ratio and dissolving in HFIP overnight. This 
solution was pumped at 29 μL/min through a 22 gauge needle serving as the spinneret. Positive 
and negative 9 kV were applied to the spinneret and another needle positioned 60 cm from the 
spinneret, respectively. Electrospun fibers were collected on a rotating aluminum mandrel (100 
rpm) placed between the needles at a 30 cm distance from the spinneret. No voltage was placed 
on the mandrel. Fibrous sheets were removed from the collector and crosslinked in a preheated 
vacuum oven under high temperature (120–150 °C) and vacuum (60 mmHg). We investigated 
crosslinking at 120 °C for 24 h (C1), 48 h (C2), 72 h (C3), and 96 h (C4). As a means to achieve 
a high degree of crosslinking with less processing time, we also explored 120 °C for 24 h 
followed by 150 °C for 24 h (C5). 
Fabrication of tubes of Espun PGS-PVA fibers for rodent-sized grafts (Figure 23) is 
reported in this dissertation for the first time as follows: to form pPGS-PVA microfibers, the 
solution was pumped at 29 uL/min through a 22 gauge needle serving as the spinneret. Positive 
and negative 12 kV were applied to the spinneret and another needle serving as the anode, 
positioned 55 cm from the spinneret, respectively. pPGS-PVA microfibers initially deposited 
onto a plastic rod held at an elevated position between the spinneret and the anode and were 
subsequently drawn onto a hyaluronic acid-coated stainless steel mandrel (Inner diameter 0.78 
mm) located 30 cm from the spinerette and 25 cm from the anode. The mandrel was rotated at 
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100 and 300 RPM, alternating every 100 uL of solution spun, in order to collect a combination of 
loosely-wound and tightly-wound fibers. No voltage or grounding was applied to either the rod 
or the mandrel. To crosslink the pPGS into PGS, fiber-coated mandrels were heated under 
vacuum (-60 mm Hg) at 120 °C for 24 h, then 150°C for an additional 24 h. 
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Figure 23.  Fabricating Espun PGS-PVAIntact microfiber tubes 
1. Electrospinning microfibers. A polymer solution containing pPGS (blue) and PVA (red) is infused through a 
spinerette needle cathode. The solution forms a polymer jet which deposits onto a plastic rod (1), then is drawn onto 
a rotating stainless steel mandrel (2). The result is a mandrel coated with microfibers of a pPGS-PVA blend (right). 
2. Thermal Crosslinking. Microfiber coated mandrels are thermally crosslinked to convert pPGS (blue) into into 
PGS (green). The result is a microfibrous tube of PGS blended with PVA (Espun PGS-PVAIntact). 
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3.2.3 Scanning Electron Microscopy 
Microfibers were prepared for scanning electron microscopy (SEM) as previously described 
[169]. Samples were adhered onto aluminum stubs with conductive carbon tape. Mounted 
samples were sputter coated with gold–palladium to a 3.5 nm thickness. Imaging was performed 
using a JSM-6330F SEM (JEOL, Tokyo, Japan) in collaboration with the Center for Biologic 
Imaging at the University of Pittsburgh. 
3.2.4 Purification of Espun PGS grafts, and removal of carrier polymer 
Removal of impurities of Espun PGS-PLGAIntact fibers. PGS-PLGA blends were washed in 
deionized water to quench unreacted LTI, leach LiBr, and dissolve the glucose mandrel. Water 
washing included three 1-hour washes with agitation, followed by a fourth wash overnight. 
Removal of carrier polymers. Carrier polymer and impurities are purified by solvent 
washes, as shown in Figure 24. The solvent regimen depends on the carrier polymer. 
Espun PGS-PLGARemoved Grafts. To remove PLGA and unreacted pPGS and oligomers, 
blends were washed in THF. THF washing included four washes of at least 4-hours duration with 
agitation. We then employed a rinsing strategy with THF, ethanol, and deionized water to 
successively swell and shrink the grafts in an effort to free deeply trapped impurities from 
between polymer chains (Figure 25).  
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Figure 24.  Removal of carrier and impurities in Espun PGS-CarrierRemoved grafts 
Tubular constructs of cross-linked PGS (green) blended with carrier polymer (red), with or without a mandrel 
affixed to the lumen (gray rod), are purified of carrier and impurities using washes in solvents. Solvents dissolve the 
carrier, but do not dissolve PGS because it is cross-linked. In the case of PGS-PVA blends, the solvent washes are a 
series of water and ethanol rinses. Water rinsing also dissolves the hyaluronic acid coating on the mandrel, thereby 
delaminating the PGS tube from the mandrel and enabling facile removal. The same process applies for purifying 
microfibrous sheets of PGS-carrier blends (not pictured). 
 
 
 
Espun PGS-PETRemoved Grafts. PGS-PET blends were washed in HFIP to dissolve PET 
and unreacted pPGS and oligomers. There were no chemical cross-linkers to quench or salts to 
remove. Microfiber blends were soaked in HFIP for three days, with fresh changes of HFIP at 
least once per day. HFIP was then removed by washing with a graded series of ethanol solutions 
dissolved in HFIP (25%, 50%, and 75% ethanol dissolved in HFIP, followed by 100% ethanol. 
Each wash was at least 1 hr) followed by a graded series of ethanol solutions dissolved in water 
(75%, 50%, and 25% ethanol dissolved in deionized water, followed by 100% deionized water. 
Each wash lasts at least 1 hour). 
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Figure 25.  Swelling purification for Espun PGS-PLGARemoved grafts 
Espun PGS-PLGARemoved  microfibers (green) begin the process with the majority of PLGA already purified from 
four THF wash. The process pictured above shrinks and re-swells the blend in an effort to free deeply trapped 
impurities from between polymer chains. Blends begin at step 1 with the final wash of the initial THF washes. The 
tube is washed for 4 hours with agitation, then the THF is decanted and substituted with ethanol (EtOH) in step 2 for 
another 4 hours with agitation. The process continues with a transfer to deionized water (H2O) in step 3. The process 
then reverses in order to swell the microfibers again. The process terminates in deionized water at step 11. 
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Espun PGS-PVARemoved Grafts. Microfibrous PGS tubes were purified and isolated as 
follows: (1) To remove PVA, the fiber-coated mandrels were subsequently washed 3 changes of 
deionized water (1 h each), followed by a fourth wash overnight with agitation. The deionized 
water washes also dissolved the hyaluronic acid coating from the mandrels, enabling the 
microfiber tube to be easily isolated from the mandrel (Figure 26). (2) To remove unreacted 
monomers and oligomers, microfibrous PGS cores were washed in a graded series of ethanol 
solutions (25%, 50%, 70%, 100%) for 1 h each, then left in 100% ethanol overnight. The washes 
were then performed again in reverse order to remove residual ethanol, ending with overnight 
washing in DI H2O. Note that some residual PVA remains present within the PGS core 
following purification [169]. 
 
 
 
 
 
Figure 26.  Removal of carrier and impurities for Espun PGS-PVARemoved grafts 
Tubular constructs of cross-linked PGS (green) blended with PVA (red) affixed to a hyaluronic acid-coated mandrel 
(gray rod) are purified of carrier and impurities using water (H2O) and ethanol (EtOH) washes. Water washing 
removes PVA and dissolves the hyaluronic acid coating on the mandrel, thereby delaminating the PGS tube from the 
mandrel and enabling facile removal. Ethanol washing removes unreacted PGS prepolymer (pPGS; blue) and 
oligomers. Ethanol is subsequently removed using a graded series of ethanol washes of increasing water content (not 
pictured). 
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3.2.5 Application of fibrous PCL sheath 
We applied PCL sheaths to PGS-only fiber tubes as previously described [118], with some 
modification (Figure 27). To improve the PGS core’s resistance to compression during sheath 
application, PGS cores were hardened by freeze-drying in a 30% w/v NaCl solution using a 
lyophilizer (Labconco Freezone 4.5, Kansas City, MO), thereby filling pores with NaCl crystals 
(Figure 28). Hardened PGS tubes were mounted onto uncoated stainless steel mandrels (0.78 
mm inner diameter) for PCL sheath application. The PCL electrospinning solution was prepared 
by dissolving PCL at 14 % w/v in a 5:1 solution of TFE:H2O. To form PCL fibers, the PCL 
solution was pumped at 29 uL/min through a 22 gauge needle serving as the spinneret. Positive 
and negative 12 kV were applied to the spinneret and an aluminum plate serving as the anode, 
positioned 55 cm from the spinneret, respectively. PCL fibers initially collected onto the 
aluminum plate, and were subsequently drawn onto the hardened PGS core template held at 1 to 
3 cm from the plate. 
 
 
 
 
 
 
Figure 27.  Application of PCL sheath to Espun PGS grafts 
A PCL solution (pink) is infused through a spinerette needle cathode. The solution forms a polymer jet at the tip of 
the spinerette, which initially deposits onto an aluminum plate anode (1), then is drawn onto the rotating PGS tube 
(green), which is temporarily hardened with salt (NaCl; orange) (2). Electrospinning yields an NaCl-hardened PGS 
microfibrous tube sheathed with PCL fibers. NaCl is removed by rinsing in water. The result (right) is a composite 
graft consisting of an Espun PGS microfiber core (green) and a PCL fiber sheath (pink).      
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Figure 28.  Salt-hardening of Espun PGS grafts 
Espun PGS grafts are hardened with NaCl crystals in preparation for PCL sheath application. Dissecting microscope 
image of grafts before (left) and after (right) applying NaCl. NaCl was applied by soaking grafts in a 35% (w/v) 
NaCl solution, then freezing and lyophilizing to remove water. Scale bar 500 µm. 
 
 
 
 78 
3.2.6 Porosity and pore size measurement 
Porosity and pore size were measured for Espun PGS-PVARemoved PCLsheath grafts. Porosity of the 
PGS core was measured gravimetrically using equation (2): 
    (2) 
where Φ represents porosity, ρbulk represents the bulk density of the portion of graft wall 
comprising PGS core, and ρpar represents the density of a nonporous particle of PGS, taken from 
literature as 1.1 g cm-3 [174].  ρbulk was calculated by dividing the mass of the PGS core by the 
PGS core volume. PGS core mass and volume were calculated by finding the mass and volume 
of the graft wall (using a microbalance and dissecting microscope), then subtracting the 
estimated mass and volume of the PCL sheath. 
Pore size and fiber diameter were measured from SEM images of graft cross-sections 
using Image J software (NIH, Bethesda, MD). To prepare graft cross-sections for SEM, grafts 
were hydrated by soaking in deionized water, then cut into ring-shaped sections using surgical 
microscissors. Graft rings were freeze-dried, then adhered onto aluminum stubs with conductive 
carbon tape before sputter coating with gold-palladium to a 3.5 nm thickness. Samples were 
imaged using a JSM-6330F SEM (JEOL, Tokyo, Japan).  Pore size and fiber diameter 
measurements were sampled along a representative radial line drawn on 4 SEM fields per graft, 
then data was pooled between all measured grafts (n = 3). Pore size was estimated by treating 
each pore as an ellipse, calculating pore area from the conjugate diameters, then reporting the 
diameter of a circular pore with the same area.  
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3.2.7 In vitro degradation of PGS core 
In vitro degradation was measured for Espun PGS-PVARemoved grafts. Hydrolytic degradation of 
PGS cores was measured by mass loss in vitro under basic conditions. To produce 3 mm 
diameter PGS disks, microfibrous PGS cores were slit along the long axis, stretched flat, and 
then cut with a 3 mm diameter hole punch. For comparison, we also tested previously reported 
PGS foam cores made from SCPL PGS. Foam cores were fabricated as previously described 
[118], then formed into disks with the same hole punch. 
For each disk, dry weight was recorded, then disks were placed in 1.5 mL Eppendorf 
tubes containing 1 mL of pH 11.75 buffer. Eppendorf tubes were incubated on a heated rocking 
plate (Thermal Rocker, ThermoFisher Scientific, Waltham, MA) set to 37 °C and set at rocking 
setting #1. Disks were retrieved at 12, 24, and 36 h. Retrieved disks were rinsed 3x with 
deionized water, then freeze-dried and weighed to determine final dry weight. The relative mass 
remaining was determined at each time point by dividing the final dry weight by the initial dry 
weight prior to incubation.  
3.2.8 Mechanical Testing 
Suture retention. Suture pull-out strength was measured in microfibrous grafts by uniaxial tensile 
testing in a MTS Insight (Eden Prairie, MN). For Espun PGS-PLGAIntact microfiber grafts, 2 
mm-long segments were clamped onto tensile grips with a 0.5 mm sized bite. A 7-0 prolene 
suture was run through the graft at 0.75 mm from the free end. The suture size was chosen to 
keep the method consistent with that used by other research groups in the field of vascular tissue 
engineering [38]. The free ends of the suture were clamped into another tensile grip. The second 
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grip then pulled the suture at a displacement rate of 0.2 mm/s. The force at which grafts yielded 
or failed was taken to be the suture pull-out strength. Espun microfiber grafts were tested against 
SCPL PGS-PCL composites used in Aim 1 (Graft dimensions listed in Table 1). 
 Espun PGS-PVARemoved grafts, suture pull-out strength was measured as described in 
[169]. This test protocol normalizes suture retention strength to cross-sectional area and uses a 
larger suture than the method described above. We chose this testing regimen for consistency 
with that used for soft tissue repair applications [175]. Fully washed samples were cut into dog 
bone shaped test specimens using a customized punch with outer dimensions (28.75 mm (l) × 
4.75 mm (w)) and a narrow region (8.25 mm (l) × 1.5 mm (w)). Sample thickness was measured 
by dial calipers. Samples were clamped onto tensile grips, then hydrated in deionized water 
immediately prior to suture retention testing. Suture retention strength was measured by inserting 
a 4-0 suture 2 mm from the edge of the long axis of 5 mm × 20 mm samples and strained to 
rupture. Suture retention strength was calculated as maximum load/(suture diameter × sample 
thickness) in N/mm2. PGS-only sheets were tested against SCPL PGS sheets, both without 
compositing with PCL. These tests were designed, performed and interpreted by Eric Jeffries, a 
doctoral student and colleague in the laboratory.   
 Ring segment tensile testing.  For Espun PGS-PLGAIntact and PGS-PLGARemoved grafts, 
uniaxial loading of ring-shaped segments was tested as previously described [118].  To obtain 
stress-strain curves, we cut grafts into 2 mm long segments. We fixed segments to two identical 
hooks connected to the load cell and the bottom plate of machine. To strain segments we applied 
uniaxial tensile force at 0.01 mm s-1. For preconditioning, segments cycled between 10 and 40 % 
ring strain until yielding reproducible stress-strain curves. We then performed strain to failure 
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and calculated wall stress, circumferential strain, and elastic modulus as previously described 
[121, 122]. Microfiber grafts were tested against native rat aortas and SCPL PGS-PCL grafts.  
We also performed longitudinal axis testing on Espun PGS-PLGAIntact to compare long-
axis tensile strength with SCPL PGS-PCL grafts. 5-mm long graft segments were clamped into 
tensile grips with a bite size of 1-2 mm and strained at 0.2 mm/s. The force at which grafts 
yielded or failed was taken as the long-axis tensile strength. 
For Espun PGS-PVARemoved sheets, uniaxial tensile loading was performed as described 
in [169]. Microfiber sheets were placed on tensile grips and then hydrated in diH2O immediately 
before stretching to failure at 25 mm/min. Multi-cycle testing from 10% to 100% strain for 100 
cycles at 100 mm/min was performed on hydrated samples to evaluate elastic recovery. 
Microfibers were compared against SCPL PGS sheets and nonporous films of PGS. 
3.2.9 Implantation 
Graft sterilization and heparin adsorption.  All grafts were sterilized by room temperature 
ethylene oxide (EtO) gas with at least 24 hours of additional aeration time. Grafts were washed 
in sterile saline overnight to quench any remaining EtO residues. To improve hemocompatibility, 
grafts in Methods A-C (see below) were soaked overnight in a heparin solution of 400 U/mL. 
Grafts in Method D were not soaked with heparin. 
 Implantation.  The implantation technique evolved over the course of the study. The 
techniques used are summarized in Table 4, and described below. 
 Method A (grafts 1-15). Grafts were implanted without the use of systemic heparin as 
previously described [118]. Grafts were implanted as interpositional implantation in rat 
abdominal aorta as follows: Rats were induced with 5% isofluorane gas, then maintained 
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anesthetized at 1.5-3% isofluorane gas. Rats received pre-operative ketoprofen and ampicillin for 
analgesic and antibiotic, respectively. A midline abdominal incision exposed the abdominal aorta 
in rats anesthetized by isoflurane inhalation. To implant the graft we separated the aorta from the 
inferior vena cava, cross-clamped the infrarenal abdominal aorta, transected a 0-4 mm segment, 
and inserted the composite graft (5-10 mm in length) in the gap. End to end anastomosis 
connected grafts to the native aorta with interrupted 9-0 nylon suture. Animals received no 
postoperative anti-coagulation or anti-platelet treatment. 
Method B (grafts 16-25). Grafts were implanted similarly to in method A, but with the 
use of systemic heparinization. Prior to aorta cross-clamping, rats received an intravenous 
injection of 50 IU/kg heparin in a tributary vein to the vena cava. Prior to the final anastamotic 
stitch, the proximal aorta was briefly unclamped to prime the graft with blood and flush air out of 
the graft. The proximal aorta was then re-clamped for the final anastamotic stitch. After 
anastomosis, the aorta was unclamped. Leaks at either anastomosis were repaired with additional 
interrupted suture, or by topical application of surgicel absorbable hemostat. Surgicel was 
removed prior to closure. 
Method C (grafts 25-32). Grafts were implanted using systemic heparinization and 
further precautions to prevent thrombosis. After midline incision, the rat’s abdominal organs 
were temporarily translocated onto sterile gauze which was periodically soaked in warm saline. 
After aorta exposure, heparinization, and cross-clamping as described in method B, the native 
aorta was transected between the clamps. The resulting aorta stumps were flushed with 
heparinized saline (saline containing a small amount of heparin solution) to prevent thrombus 
formation. Prior to the final anastamotic stitch, the graft was filled with heparinized saline using 
a syringe, thereby removing air from the graft lumen. After anastomosis, the aorta was 
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unclamped, and hemostasis was achieved as described in method B. Organs were translocated 
back into the abdomen prior to closure. 
Method D (grafts 33-42) Implantations performed by Christopher Breuer’s laboratory at 
the Research Institute of Nationwide Children’s Hospital. These implants were performed 
without heparinization by operators with microsurgery training and extensive experience in the 
mouse infrarenal abdominal aorta model. Nine nanofiber PGS scaffolds were implanted as 
infrarenal aortic interposition grafts using standard aseptic microsurgical technique as previously 
described. The mice were administered an intraperitoneal injection of pre-anesthesia analgesic 
(ketoprofen, 10mg/kg), anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), and 
opened with a midline incision.  The abdominal organs were eviscerated and a 3.0 mm portion of 
the infrarenal aorta was identified, isolated, crossclamped, and divided.  Scaffolds were then 
implanted as interposition grafts using a running 10-0 nylon suture for the end-to-end proximal 
and distal anastomoses.  All animals received routine postoperative care and were maintained for 
the duration of the study without any anti-coagulation or anti-platelet therapy. All animals 
received humane care in compliance with the National Institutes of Health (NIH) Guide for the 
Care and Use of Laboratory Animals.  The Institutional Animal Care and Use Committee of The 
Research Institute at Nationwide Children's Hospital approved and monitored the use of animals 
and all animal procedures described in this study.  8-12 week old C57BL/6 female mice (n = 9) 
were purchased from Jackson Laboratories (Bar Harbor, ME, USA). 
 
 
 
 
 84 
 
Table 4. Implantation methods used for pilot in vivo assessments 
 
 
Implant 
no. 
Implant 
Method 
Thrombosis 
Incidence* 
Systemic 
heparin 
Flush stumps 
& prime grafts 
with 
heparinized 
saline 
Graft Types 
Surgeon experience 
Microsurgery 
training? 
Prior 
experience 
with model 
1-15 A High N N 
Espun PGS-PLGAIntact 
N N 
Espun PGS-PLGARemoved PCLSheath 
16-24 B High Y N 
Espun PGS-PLGAIntact 
N N Espun PGS-PLGA
Removed 
Espun PGS-PLGARemoved PCLSheath 
25-32 C Low-Moderate Y Y 
Espun PGS-PLGAIntact 
N N 
Espun PGS-PLGARemoved PCLSheath 
33-43 D None N N Espun PGS-PVARemoved PCLSheath Y Y 
* Estimated. For many grafts, thrombosis was not definitively confirmed, but strongly suspected 
3.3 RESULTS 
3.3.1 Microfiber formation and PGS cross-linking 
PCL, PLGA, PET, and PVA carriers all yielded microfibers from electrospinning, although fiber 
quality varied with carrier polymer (Figure 29). Espun pPGS-PCLIntact fibers were the most 
challenging to electrospin and produced the most fusion between fibers, and thus were not 
studied in future experiments. Espun pPGS-PVAIntact fibers showed the least fiber fusion, but 
fiber quality after thermal crosslinking depended on the time and temperature used.  Espun PGS-
PLGAIntact fibers and Espun pPGS-PET fibers also demonstrated limited fiber fusion after 
thermal cross-linking. The amount of PGS in Espun PGS-PLGAIntact or Removed blends was 
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maximized to reduce the difference in graft composition from the original SCPL PGS design, as 
some Espun PGS-PLGAIntact grafts were to be implanted without removing PLGA.  The 
maximum pPGS:PLGA ratio that yielded minimal fiber fusion was 7:3 (Figure 30). 
  
 
 
Figure 29.  Microfiber formation and PGS crosslinking in Espun pPGS and PGS grafts 
SEM of microfiber blends before and after cross-linking. All scale bars 25 µm (note not all magnifications are the 
same). For PGS-PVA blends, the degree of fiber fusion depends on thermal cross-linking conditions (overlaid white 
text).  * indicates not measured. pPGS-PCLIntact blends were not combined with chemical crosslinker, as further 
study of the blend was de-incentivized by its low fabrication efficiency and poor fiber quality. For PGS-PLGAIntact 
blends, fibers already cross-link during and after electrospinning, as the blend already contains chemical cross-linker 
LTI. Images for PGS-PVAIntact blends collected by Eric Jeffries and adapted from [169]. 
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Figure 30.  Maximization of PGS content in Espun pPGS-PVAintact grafts 
SEM of microfiber blends with varying pPGS:PLGA ratios. The maximum content of pPGS which sufficiently 
limited fiber fusion was 70% by mass (right). Scale bar 25 µm. 
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3.3.2 Removal of carrier polymer 
Solvent washes removed varying amounts of carrier polymer from PGS microfibers.  Solvent 
washing of Espun PGS-PLGAIntact grafts reduced the mass by more than the total mass of PLGA 
added, suggesting that the vast majority of PLGA was removed in Espun PGS-PLGARemoved 
grafts. The exact amount of PLGA residue is unknown, as it is unknown what the mass of 
unreacted pPGS monomer and oligomers was before and after solvent washing. Substantial 
residues of PET are suspected to remain after solvent washing of Espun PGS-PETIntact grafts, as 
resultant Espun PGS-PETRemoved grafts demonstrated tearing failures at the same strains as PET-
only microfibers. Consequently, mass measurement was not performed. Removal of PVA from 
Espun PGS-PVAIntact grafts or sheets was characterized in detail by Jeffries et al [169]. Assuming 
the same mass of unreacted pPGS monomers and oligomers leaches out of Espun PGS-PVAIntact 
fibers as does from nonporous PGS films, Espun PGS-PVARemoved fibers can contain up to 14 % 
or 31% residual PVA for thermal crosslinking conditions 120 ºC at 48h and 120 ºC 24h + 150 ºC 
24h, respectively. 
 The fiber structure for Espun PGS-CarrierRemoved grafts varied depending on the carrier 
polymer and thermal cross-linking conditions (Figure 31). Espun PGS-PVARemoved fibers 
showed the least amount of fiber fusion. Espun PGS-PETRemoved fibers also showed resistance to 
fiber fusion. Transverse cross-sections of Espun PGS-CarrierRemoved tubes or sheets showed more 
fusion of fibers than did views of construct outer surface, suggesting that winding of successive 
layers of fibers may cause compression-induced fiber fusion within the construct wall. 
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Figure 31.  Fiber morphology of Espun PGS-CarrierRemoved blends 
SEM images of PGS microfibers after removing carrier polymer. Left column shows surface view of sheets or tubes. 
Right column shows transverse sections of tubes or sheets. All scale bars 10 µm. 
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3.3.3 Application of PCL sheath, & finished composite grafts. 
Implant-grade Espun PGS cores were prepared using both PLGA and PVA carrier polymers. 
PCL sheaths were applied to some groups of these PGS microfiber grafts (Figure 32).  Espun 
PGS-PVAremoved PCLsheath grafts, the luminal surface showed superficial fusion in some regions, 
but frequent gaps in fusion provide access to the space within the PGS core. Unsheathed grafts 
were also prepared for implantations. 
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Figure 32.  Structure of Espun PGS-CarrierRemoved PCLSheath grafts 
Structure of Espun PGS-CarrierRemoved PCLSheath grafts, fabricated from PLGA (left column) or PVA (right column) 
carriers. Macroscopic. Camera or dissecting scope pictures of implant-ready grafts. Note that PLGA-derived grafts 
are designed for rat abdominal aorta interposition grafting, whereas PVA-derived grafts are designed at different 
dimensions for mouse abdominal aorta interposition grafting (described further in Chapter 4). Transverse. 
Transverse cross-sections of grafts show thin PCL sheath and PGS core regions, labeled with overlaid white text. 
Insets show low magnification of grafts. PCL Sheath. View of abluminal surface of graft shows coverage with PCL 
micro- and nano-fibers. Luminal Surface. View of blood-contacting surface of the graft. In PGS-PVARemoved 
microfibers, fused fibers create a smooth surface in some regions, but frequent gaps in fusion provide access to the 
space within the core. 
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3.3.4 Pre-implant characterization of Espun PGS-PVARemoved PCLsheath grafts 
Espun PGS-PVARemoved PCLsheath grafts were characterized in physical properties, geometry, and 
resorption rate in vitro. These grafts are comprised of an electrospun microfibrous PGS core and 
a PCL sheath (Figure 32, right). SEM shows that microfibers comprise the PGS core (~1.5 µm; 
Table 5), with space between some fibers and limited fusion between others. The luminal 
surface of the graft demonstrates some regions of superficial fiber fusion, but frequent gaps in 
fusion provide access to the space within the PGS core. The sheath consists of PCL micro- and 
nano-fibers and accounts for less than 5% of the total graft thickness (Table 6). 
These Espun PGS-PVARemoved PCLsheath grafts vascular grafts showed some differences in 
physical properties and geometry from the SCPL PGS-PCL composite grafts described in 
Chapter 2 [118]. Table 5 compares the physical properties of the PGS cores of both grafts. 
Espun PGS-PVARemoved PCLsheath grafts demonstrated reduced porosity and pore size, and 3-fold 
larger Young’s Modulus compared with SCPL PGS. Espun grafts were designed for 
interpositional implantation into a mouse rather than rat infrarenal abdominal aorta, and thus are 
implanted at shorter length and reduced wall thickness (Table 6). Espun PGS-PVARemoved fibers 
may contain some nontoxic residues of poly(vinyl alcohol) (PVA) not present in SCPL PGS 
[169]. Despite graft differences, both designs share a similar rate of hydrolytic degradation in 
vitro (Figure 33, Table 5). 
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Table 5. Physical properties of PGS core 
 
 Symbol Units Espun PGS-PVA
Removed 
Microfibers SCPL PGS Foam [118] 
Pore Size 
 
µm 1.87 ± 0.23 21.2 ± 0.79 
Porosity 
 
% 47.1 ± 4.2 81.1± 0.7 
Fiber Diameter 
 
µm 1.45 ± 0.6 N/A 
Degradation rate 
 (mass loss at pH 11.75)  
% h -1 1.34 1.33 
Young’s Modulus  MPa 0.67 – 0.87 [169] 0.243  ± 0.072 
 
 
 
Table 6. Graft geometry and implantation 
 
 
 Espun PGS-PVARemoved PCLSheath SCPL PGS-PCL [118] 
Animal Model Mouse Rat 
Implantation site Infrarenal Abdominal Aorta Infrarenal Abdominal Aorta 
Length (mm) 3 - 5 8 - 10 
Inner diameter (µm) 718.9 ± 19.2 723 ± 1.33 
Outer diameter (µm) 1164 ± 35.6 1313 ± 7.50 
PGS core thickness (µm) 222.5 ± 21.1 264 ±  10.3 
PCL sheath thickness (µm) 10.8 ± 2.88 15.7 ± 6.11 
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Figure 33.  Hydrolytic degradation of Espun PGS-PVARemoved and SCPL PGS in basic conditions 
Fraction of mass remaining (mass fraction) vs. incubation time for the improved design (Espun PGS-PVARemoved 
cores, orange) and the original design (SCPL PGS cores, blue). Disks of graft cores were incubated in pH 11.75 
buffer at 37 °C with agitation to accelerate hydrolysis in vitro. n.s. – no statistically significant difference between 
mass fraction of SCPL PGS and Espun PGS (P > 0.05). 
 
 
 
3.3.5 Translational potential of fabrication strategies 
All strategies for fabricating Espun PGS cores showed translatability advantages in lead time, 
duration of skilled labor, and the number of steps requiring skilled labor (Figure 34).  Of all the 
microfiber strategies, the only which required more fabrication steps than SCPL PGS was Espun 
PGS-PLGARemoved. The increase in fabrication steps was due to additional purification steps 
necessitated by the need for thorough purification, as the electrospinning solution contains toxic 
LiBr salt and lysine triisocyanate cross-linker.  
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Figure 34.  Translational potential for fabrication strategies of Espun PGS 
Lead time (A), skilled labor required (B), and number of steps required (C) to produce the PGS cores for five usable, 
implant-grade grafts. PCL sheathing requires an additional 6 hours lead time, 2 hours skilled labor, 2 steps, and 1 
skilled step (not pictured).  A.  Lead time (h), for each core fabrication strategy. All electrospun (Espun) fabrication 
methods require less time to fabricate than SCPL PGS. B. Skilled labor required (h). All Espun fabrication methods 
require less time of skilled manual labor than SCPL PGS.  C. Total number of steps (blue) and number of steps 
requiring skilled labor (red). All µfiber fabrication methods used fewer steps requiring skilled labor than SCPL PGS. 
The total number of steps was also less for Espun fabrication, except for Espun PGS-PLGARemoved grafts. 
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3.3.6 Mechanical characterizations 
All microfiber cores measured demonstrated superior suture retention strength than SCPL PGS. 
PGS-PLGA microfiber cores demonstrated ~2-fold greater suture retention than compared with 
SCPL-PCL composite grafts (Figure 35 A). PGS-only microfibers derived from PVA blends 
demonstrated far-superior suture retention strength to SPCL PGS, which failed to achieve any 
measurable load before failing by tearing (Figure 35 B; collected by Eric Jeffries and reported in 
[169]). 
 
 
 
 
 
 
 
Figure 35.  Suture retention strength of Espun cores 
A. Suture retention comparison of Espun PGS-PLGAIntact grafts and composites of SCPL PGS and PCL fibers 
(SCPL PGS-PCL). Espun PGS-PLGAIntact (dark gray) showed significantly greater suture retention strength than 
SCPL PGS-PCL (light gray). Suture retention strength is reported as load at which constructs yielded or tore. * P < 
0.05. B. Suture retention comparison of Espun PGS-PVARemoved blends and SCPL PGS foams (SCPL PGS). Espun 
PGS at both thermal cross-linking conditions tested substantially exceed the suture retention strength of SCPL PGS, 
which failed to withstand any measurable load at the testing conditions used by Jeffries et al. Here, suture retention 
strength is normalized to sample thickness and suture diameter. B is adapted from [169]. 
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 Assessment of the circumferential wall stresses of graft cores showed that all Espun PGS-
CarrierRemoved grafts had Young’s moduli within 1 order of magnitude of rat native aortas (Figure 
36). Espun PGS-PLGAIntact grafts were substantially stiffer than native aortas by 3 orders of 
magnitude. Espun PGS-PLGAIntact blends showed superior strength to SCPL PGS composites 
along the longitudinal axis, suggesting improved resistance to tearing during implantation 
(Figure 37). 
 
 
 
 
 
Figure 36.  Mechanical properties of core materials in the circumferential direction 
A. Young’s moduli of ring sections of tubular cores. All Espun PGS and SCPL PGS cores are within 1 order of 
magnitude of the modulus of native rat abdominal aorta. Espun PGS-PLGAIntact grafts (left) were three orders of 
magnitude stiffer than native tissue. Moduli taken from stress-strain data at wall stresses between 20 kPa and 200 
kPa (shown in B), which we determined empirically to be the range of wall stresses at physiologic conditions. 
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Figure 37.  Longitudinal ultimate tensile strength 
Espun PGS-PLGAIntact grafts (dark gray, left) demonstrate significantly larger longitudinal ultimate tensile strength 
(UTS) than SCPL PGS-PCL grafts (light gray, right). * P < 0.05. 
 
 
 
3.3.7 Surgical handling 
We performed a total of 41 implants to assess surgical handling and in vivo performance. Espun 
grafts comprised of PGS-PLGAIntact, PGS-PLGARemoved, or PGS-PLGARemoved PCLSheath; all were 
implanted with 100% success and demonstrated superior surgical handling to SCPL PGS-PCL 
when handled by a pediatric cardiothoracic surgeon lacking prior experience with the animal 
model (Table 7). Espun PGS-PVARemoved PCLSheath grafts were also implanted with 100% 
success, but their handling was not compared to SCPL PGS-PCL as they were implanted by a 
separate team from the Research Institute of Nationwide Children’s Hospital who had not 
handled SCPL PGS-PCL. However, the team did describe the surgical handling qualitatively as 
“good.” Taken together, this data suggests that microfiber fabrication improved surgical handling 
compared with SCPL PGS-PCL.  
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Table 7. Surgical handling of implanted grafts 
 
 
 Total implanted 
Implant 
without 
damage 
Tear 
but 
repaired 
Unsuccessful % Success 
Surgeon 
Training 
Experience 
with animal 
model 
Espun PGS-
PLGAIntact 19 19 0 0 100 
Pediatric 
Cardiothoracic  No 
Espun PGS-
PLGARemoved 4 1 3 0 100 
Pediatric 
Cardiothoracic  No 
Espun PGS-
PLGARemoved 
PCLSheath 
7 7 0 0 100 Pediatric Cardiothoracic  No 
SCPL PGS-PCL 2 0 0 2 0 Pediatric Cardiothoracic No 
Espun PGS-
PVARemoved 
PCLSheath 
9 9 0 0 100 Microsurgery Yes 
 
 
3.4 DISCUSSION 
This chapter summarizes years of effort to improve the translational potential of fast-remodeling 
bio-inductive vascular grafts. Our strategy was to develop novel methods for fabricating grafts or 
graft cores from microfibers comprised of or containing cross-linked PGS. While clearly useful 
for vascular graft design, developing a fabrication technique for PGS microfibers would also be a 
far-reaching advance in tissue engineering and regenerative medicine, with relevance to any 
medical application requiring tensile loading and/or suture anchoring of resorbable materials. 
PGS is a unique and desirable material for engineering of soft tissues, as its elastic modulus can 
be tuned to match that of various tissues [169], and it resorbs rapidly in vivo with minimal 
inflammation [120]. To realize the potential of implantable PGS, various groups have pursued 
strategies to electrospin PGS ([169] for review). Though promising, the limitations of these 
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strategies motivated us to develop our own improved methods. For example, previously 
developed Espun pPGS–PCLIntact blends exhibit mechanical properties more similar to PCL than 
PGS [176], and noncrosslinked pPGS may have a cytotoxic effect if pPGS is not removed from 
the scaffold [177]. Gelatin has been used as a carrier but it requires crosslinking methods that use 
glutaraldehyde, acrylate-ultraviolet (UV), or EDC-NHS, which may alter PGS structure and 
properties and trigger inflammation and calcification [178] [179] [180]. Coaxial electrospun 
pPGS–PLLA tolerated both thermal crosslinking and dissolution of the PLLA sheath without 
substantial fiber fusion [181]. However, the dichloromethane used to dissolve PLLA is toxic and 
a suspect carcinogen, requiring stringent and complete removal before biomedical applications.  
Two of the Espun PGS microfiber methods we developed in this chapter demonstrate advantages 
over these prior approaches. Espun PGS-PLGARemoved microfibers can be spun with traditional 
electrospinning equipment rather than a core-shell setup, thereby simplifying the fabrication 
process and reducing costs. Espun PGS-PVARemoved microfibers fabricate with more simplicity 
and shorter lead times than all other methods and circumvent the need for toxic solvent washes. 
We have recently published this method [169], and believe it will be adopted by others for its 
advantages in fabrication and biocompatibility.  
In the present study, our primary objective was to improve the translatability of SCPL 
PGS-PCL composite grafts by developing PGS-based Espun microfiber grafts. Consequently, we 
employed a range of carrier polymers, including some blends previously reported by others. We 
began our experiments using PCL as a carrier simply because our laboratory has prior experience 
in elecrospinning PCL and had sufficient quantities on hand for initial exploration. Shortly 
thereafter, we began trying blends with PLGA because it is faster-resorbing than PCL, and thus 
residues left over after removing the bulk of PLGA should still resorb in vivo in a timely manner. 
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Additionally, PLGA removal could be foregone altogether, and the graft may still demonstrate 
fast-remodeling capability. 
 In later experiments, we began employing thermostable polymers, which enable thermal 
cross-linking of PGS, thereby circumventing the toxicity concerns of using chemical cross-
linkers as required for PCL and PLGA blending. We chose PET as the first thermostable carrier 
because (1) it is clinically accepted as a vascular graft material with reasonable 
hemocompatibility and long-term biocompatibility, and (2) it is exceptionally low-cost, as one of 
the most common polyesters used in industry. However, the stiffness and non-degradability of 
PET are major limitations, and residues not removed by solvent washing could contribute to 
neointimal hyperlasia and long-term inflammation in the graft. We considered leaving PET in to 
serve as a non-resorbable backbone promoting continued graft strength during PGS resorption, 
but the distribution of PET within fibers is unknown, and small fragments of PET might be freed 
during PGS degradation. These nondegradable fragments could cause embolism formation 
and/or accumulate in the liver and kidneys, all potential causes of morbidity. 
PVA shares PET’s advantage of thermostability, but without the disadvantage of non-
degradability. PVA is a common FDA-approved additive in food and drugs, alleviating 
biocompatibility concerns. It is also water-soluble, enabling facile removal from PGS-PVA 
blends without requiring washes with toxic organic solvents. Clearly, PVA has theoretical 
advantages as a carrier for PGS electrospinning compared to the previously listed polymers. 
However, PGS-PVA blends were used in our vascular grafts last, as the ideal PVA formulation 
and optimized electrospinning parameters were not determined until after Espun PGS-PLGA 
microfiber grafts were thoroughly investigated. Espun PGS-PVARemoved blends have been 
thoroughly characterized by Jeffries et al. in [169]. 
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In choosing an electrospinning method for improved translatability of bio-inductive 
grafts, microfiber quality was the first selection criterion. Ideally, microfibers must resist fusion 
into nonporous sheets, which are prone to failure by tearing and resorb slowly due to low surface 
area and impermeability to cell infiltration. We ruled PCL out as a carrier early in our 
investigation, as fibers demonstrated substantial fusion even at a 1:1 ratio of pPGS:PCL. We 
were surprised to find substantial fiber fusion using the same electrospinning conditions reported 
by Sant et al. [176] for similar blends, in which fusion was not reported as a problem. PLGA 
carrier blends were the first to demonstrate distinct fibers at relevant wall thickness, though 
fusion still occurred, especially within the wall. Consequently, most early work on Espun PGS-
based grafts focused on PLGA blends. PET blends were the first to demonstrate minimal fiber 
fusion, and for those fibers to survive thermal cross-linking. However, PVA blends demonstrated 
comparable fiber quality with thermal cross-linking. This equivalence, when coupled with the 
theoretical advantages of PVA as a carrier, drove us to focus further development efforts on PVA 
blends over PET blends. We initially selected thermal cross-linking conditions of 120 °C for 24 
h and 150 °C for an additional 24 h because we expected the 150 °C cure temperature to yield 
PGS with high tensile strength, which we believed would be advantageous in vascular surgery. 
Consequently, all of the implanted Espun PGS-PVARemoved grafts were cured at this temperature. 
However, we later found that softer PGS microfibers have superior surgical handling, as they can 
be strained substantially farther without failing [169], thereby reducing the likelihood of suture 
pull-out during surgery. Thus we began constructing Espun PGS-PVARemoved grafts using 120 °C 
for 48 h, which we characterized in vitro but have not yet implanted. 
 We removed the carrier polymer in some of our microfiber grafts in order to match the 
composition of core material as closely as possible to that of our original SCPL PGS design. 
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However, we also left PLGA carrier in the microfibers of some grafts, as Espun PGS-PLGAIntact 
microfibers might also fit the criteria for a fast-remodeling bio-inductive vascular graft. 
Removing PLGA from PGS blends requires the use of organic solvents. We employed additional 
steps to swell and contract the construct to maximize removal of impurities, as these blends 
require substantial quantities of toxic cross-linker lysine triisocyante and toxic LiBr salt. 
Purification yielded Espun PGS-PLGARemoved microfibers in which the majority of PLGA is 
removed, but fiber fusion increased compared with prior to solvent washing. Despite requiring 
lengthy purification steps and having the potential for residual toxicity, Espun PGS-PLGARemoved 
grafts were among the first suturable vascular grafts developed by our laboratory, and thus were 
fabricated and implanted in substantial number. Our second attempt in removing carrier polymer 
was with PET blends. Washing PET blends in HFIP did change their mechanical properties, but 
substantial PET residues seemed to remain, as resultant microfibers retain a propensity for 
tearing failure at tensions lower than expected for surgery. Consequently, we discontinued 
further work with PET blends.  
PVA removal from Espun PGS-PVA blends was the simplest process with minimal 
toxicity risk, as only water and ethanol washes were required. However, a substantial amount of 
PVA carrier likely remains after washing. Residual PVA may be cross-linked into polymer 
chains by polycondensation with pPGS, entrapped between PGS polymer chains, or rendered 
insoluble from heat curing [169]. The presence of PVA residues might not source undesired 
effects. PVA showed no significant cytotoxicity in vitro. It is possible that PVA may affect 
protein adsorption or material degradation rate.  
All Espun microfiber grafts demonstrated advantages in fabrication and surgical handling 
compared to SCPL grafts, thereby validating our hypothesis that microfiber fabrication would 
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improve graft translational potential. Espun PGS-PVARemoved PCLSheath grafts showed the greatest 
advantages in translational potential, and consequently are the focus of the next chapter. These 
blends demonstrated the simplest fabrication with the shortest lead times, and were implanted 
with 100% success.  Espun PGS-PLGAIntact grafts were implanted without mechanical failure, 
but these grafts might retain cytotoxic residues of chemical cross-linker lysine triisocyanate and 
LiBr salt. Espun PGS-PLGARemoved grafts required substantially larger lead times and more steps 
than PVA strategies. Their surgical handling was limited by a 75% incidence of repairable 
tearing during implant surgery, although this was still superior to SCPL PGS-PCL grafts which 
all tore irreparably when handled by the same surgeon.  
3.5 LIMITATIONS AND FUTURE DIRECTIONS 
Future work will address the limitations of this investigation. An ideal fabrication method should 
produce a range of structures with tunable properties. At present, the tunability of graft structural 
and physical properties remains to be further explored. Consequently, ongoing work by others in 
our laboratory focuses on determining the effects of tunable electrospinning parameters such as 
infusion rate, voltage difference, spinneret-collector distance, and mandrel rotational speed. Such 
work will empower our laboratory to implement design changes warranted from in vivo results of 
our implantations, which are further detailed in Chapter 4. The electrospinning processes we 
developed are clearly more translatable than SCPL techniques, but at present they are still 
manual processes requiring skilled labor. Skilled labor tends to increase costs and challenge 
quality control, as it adds human error to variability within and between batches. The present 
processes require a human operator to periodically adjust voltage and/or move the collecting 
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mandrel or rod to ensure even fiber deposition. Human operators were also needed to assess 
whether fibers were being formed efficiently, which varies with humidity, temperature, and air 
flow rate. Automating these adjustments or eliminating the need for them could remove the 
human element from the process. To approach automation, our laboratory is building a custom 
electrospinning enclosure with tighter environmental control and a programmable moving stage.   
Even with automation, electrospinning is still less reproducible and less cost-effective 
than traditional polymer spinning techniques used by the medical textiles industry. Enabling PGS 
prepolymer to be melt spun and drawn would even further improve the translational potential of 
graft fabrication. Unfortunately, the low Tg of PGS prepolymer complicates these methods 
similarly to in electrospinning, as pPGS fibers flow and fuse during thermal cross-linking. 
Efforts to increase the Tg of pPGS, or modifications to enable cross-linking without heat or 
chemical cross-linkers, might realize the translational advantages of textiles industry techniques. 
3.6 CONCLUSION 
Here we developed several novel methods for fabricating vascular grafts from microfibers 
comprised from or containing PGS. Espun PGS-PVARemoved PCLSheath grafts demonstrated the 
simplest and fastest fabrication, but all Espun fabrication methods demonstrated advantages over 
SCPL PGS-PCL grafts in surgical handling, lead time, and fabrication simplicity. These findings 
validate our hypothesis that fabricating graft cores from microfibers improve the translational 
potential of fast-remodeling bio-inductive vascular grafts. These methods may positively impact 
the broader field of tissue engineering and regenerative medicine, as they yield suturable PGS 
implants which could prove useful in a range of soft-tissue applications. Improving graft strength 
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and fabrication simplicity improves the translational potential of bio-inductive grafts, but only if 
they retain their previously demonstrated long-term performance. Consequently, we investigated 
graft performance in vivo in Chapter 4. 
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4.0  PERFORMANCE TESTING OF IMPROVED DESIGN 
In Chapter 3 we improved graft surgical handling and simplified fabrication by constructing 
tubular graft cores from electrospun microfibers. This process substantially improves the 
feasibility of applying bio-inductive grafts in a clinical setting. However, to potentially improve 
patient care, the new design must retain the excellent long-term performance demonstrated by 
the original design in Chapter 2.  In Chapter 4 we report performance testing of our newly 
developed microfibrous grafts. 
4.1 INTRODUCTION 
The potential translational advantages of microfibrous grafts may only be realized if they retain 
the favorable long-term performance demonstrated by the original SCPL design. Consequently, 
we implanted the most promising graft designs from the previous chapter in rodent models. 
Performance testing of implants requires reproducible surgical technique. The majority of our 
pilot implantation studies in Chapter 3 were complicated by uncertainty in surgical technique, as 
they occurred early in the learning curve for a surgeon who was not trained in microsurgery or 
the animal model. Grafts implanted with methods A through C (Table 4) realized high rates of 
acute thrombosis independent of graft composition. Consequently, graft propensity for 
thrombosis could not be evaluated, and graft remodeling was only assessed in the few patent 
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grafts. Surgical technique became reproducible through collaboration with Christopher Breuer’s 
laboratory at the Research Institute of Nationwide Children’s Hospital. Their team of 
microsurgeons have extensive experience in an even more technically challenging mouse model 
for interpositional arterial vascular grafts. This team’s expertise enabled our laboratory to 
evaluate the time course of microfiber graft performance and remodeling in vivo. 
 The objective of this chapter’s investigation is to assess the long-term performance of our 
most promising bio-inductive vascular graft designs from Chapter 3.  We hypothesized that these 
grafts would approach the long-term performance of the original microporous PGS-PCL 
composite design despite the reduced pore size. Our rationale is that even nonporous PGS 
resorbs rapidly in vitro [119, 120, 174], and nonporous fast-remodeling vascular grafts have 
previously formed neoarteries in situ [114, 136, 139].  To test our hypothesis, we assessed the in-
host remodeling of 3 graft designs: (1) Espun PGS-PLGAIntact (2) Espun PGS-PLGARemoved, and 
(3) Espun PGS-PVARemoved PCLSheath. In the latter group, favorable patency enabled us to 
observed remodeling over a time course of 3 months, 6 months, and 1 year. Within this group, to 
understand the graft remodeling processes in both dilating and undilated grafts, we selectively 
sacrificed animals based on diameter change observed from non-invasive Doppler ultrasound. At 
explant, we characterized grafts in complication incidence, tissue architecture, and mechanical 
properties. 
 Importantly, this study also contributes to a larger body of work. Our laboratory is 
collaborating with both Jay Humphrey’s team at Yale University and Christopher Breuer’s team 
at the Research Institute of Nationwide Children’s Hospital to develop a framework for 
rationally designing bio-inductive vascular grafts. This framework uses in vivo observations to 
inform a computational model of graft remodeling, which will simulate further experiments in 
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silico to determine the optimal states for graft structure, mechanical properties, and resorption 
kinetics.  Consequent to the collaborative nature of this work, a substantial portion of the study 
design, data collection, and analysis was performed outside of the University of Pittsburgh. 
Collaborators include Ramak Khosravi, Cameron A. Best, Yong-Ung Lee, Tai Yi, Matthew R. 
Bersi, Toshiharu Shinoka, Jay D. Humphrey, and Christopher K. Breuer. We identify each 
collaborator’s contribution in the methods and results section of this chapter. Currently our cross-
institutional team is preparing a manuscript which presents this data in the context of developing 
a framework for rational design of bio-inductive vascular grafts [182]. However, such context is 
outside the scope of this dissertation. Herein we report graft performance in the context of 
assessing translational potential of the current design. 
4.2 METHODS 
4.2.1 Graft implantation 
Grafts were implanted as described in 3.2.9. 
4.2.2 Ultrasound Monitoring 
Ultrasound monitoring was provided by Christopher Breuer’s team at The Research Institute at 
Nationwide Children's Hospital. Implants were monitored longitudinally until explant with high 
frequency Doppler ultrasonography (Vevo® 2100, VisualSonics Inc, Toronto, Canada).  After 
induction of anesthesia (1.5% inhaled isoflurane vaporized with oxygen at 1 L/min, Baxter) the 
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ventral abdomen was chemically depilated and ultrasound gel applied (Aquasonic Clear®).  
Body temperature was maintained at 38°C for the duration of ultrasound interrogation.  Long 
axis images were acquired in B-mode, pulse wave, and color Doppler.  Image J (NIH, Bethesda, 
MD) was used to quantify TEVG and adjacent artery lumen diameters.  TEVG lumen diameters 
are reported as the mean ± SD of three measurements (proximal anastomosis, mid-graft, distal 
anastomosis) and are normalized to the mean lumen diameter of the adjacent artery. 
4.2.3 Graft Harvest 
For grafts implanted using methods A-C of Chapter 3: All animals were cared for in accordance 
with IACUC-approved protocols at the University of Pittsburgh and the Research Institute of 
Nationwide Children’s Hospital. Animals were euthanized at predetermined time points, or pre-
emptively if grafts occlusion was suspected by Doppler ultrasound or if the animal was 
exhibiting distress. Euthanasia methods included CO2 asphyxiation, or anesthetized surgical 
exsanguination during harvest. The latter method was used in some sacrifices, as it allows 
patency to be examined. Patency was checked in those grafts by clamping the aorta distal to the 
graft, then transecting the native aorta between the clamp and the graft. Pulsatile leakage of 
blood confirmed graft patency. 
For grafts implanted using method D of Chapter 3:  Grafts were harvested by 
Christopher Breuer’s team at 3, 6, and 12 months (n=3/time point).  At the appropriate endpoint, 
animals were euthanized by intraperitoneal injection of ketamine (300 mg/kg) and xylazine (30 
mg/kg) overdose cocktail followed by induction of pneumothorax. Mice were then systemically 
perfused with cold 1x PBS. A continuous vascular segment comprised of the TEVG and a 1-2 
mm portion of native infrarenal abdominal aorta distal and proximal to the sites of anastomosis 
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was harvested and placed in 1x HBSS until biaxial mechanical testing. In order to ensure 
adequate pressurization during mechanical testing, branching vessels were also identified and 
ligated. Prior to explant, small sutures were placed at multiple locations along the TEVG, 
proximal IAA, and distal IAA and photographs were taken to record their positions both in vivo 
and following excision. Distances between these suture markers were measured using ImageJ 
software and used to determine the in vivo axial stretches (the ratio between the loaded and 
unloaded axial length of each segment).  
4.2.4 Histology and Immunohistochemistry 
For grafts implanted using methods A-C of Chapter 3: Explants were fixed in 2% 
paraformaldehyde for 2 h at room temperature, then frozen in OCT with liquid nitrogen and 
stored at -80 °C until use. Sections were cut to 8 µm thickness using a cryomicrotome (HM525, 
Thermo Scientific, Waltham MA), mounted on glass slides, and stored at -80°C until staining.  
For grafts implanted using method D of Chapter 3: Christopher Breuer’s team planned 
and performed histology and immunohistochemistry on neoarteries.  After biaxial mechanical 
testing, samples were fixed in 10% NBF at 4°C for 24hrs, dehydrated, paraffin embedded, and 
serially sectioned (4 μm thick sections).  Representative sections were analyzed at 5 regions of 
interest: proximal aorta, proximal anastomosis, TEVG, distal anastomosis, and distal aorta.  
Histological analysis included: hematoxylin and eosin (HE), Masson’s trichrome (TRI), 
Picrosirius Red (PSR), Hart’s, and von Kossa (VK) stainings.  For immunohistochemical 
analysis, slides were rehydrated and blocked for endogenous peroxidase activity (0.3% H2O2 in 
MeOH) and nonspecific background staining (Background Sniper, BioCare Medical).  Antigens 
were retrieved with citrate buffer (pH 6.0, 90°C, 15:00 min).   Slides were incubated overnight at 
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4°C with the following primary antibodies: rabbit anti-collagen I (1:250, Abcam), rabbit anti-
collagen III (1:250, Abcam), anti-human smooth muscle actin (cross reacts with mouse, 1:500, 
Dako), rabbit anti-calponin (1:200, Abcam) and rat anti-F4/80 (1:1000, AbD Serotec).  Primary 
antibody binding was detected by incubation with species appropriate biotinylated secondary 
antibodies (Vector) followed by binding of horseradish peroxidase streptavidin and subsequent 
chromogenic development with 3,3-diaminobenzidine (Vector).  Finally, nuclei were 
counterstained with Gill’s hematoxylin, and slides were dehydrated and coverslipped. 
4.2.5 Imaging and quantification of histology/IHC sections 
For grafts implanted using methods A-C of Chapter 3:  Slides were stained with hematoxalin and 
eosin (H&E) and von Kossa according to standard protocols, and imaged using a Nikon Eclipse 
Ti inverted microscope with Nikon Elements software (Melville, NY). Tissue sections were 
examined for elastin autofluroescence using an Olympus Fluoview FV1000-MPE Multiphoton 
microscope with a 1.12 NA 25x MPE water immersion objective. [134]  Excitation was set to 
870 nm, and the emission range was set to 525-575 nm for elastin. 
For grafts implanted using method D of Chapter 3:  Christopher Breuer’s and Jay 
Humphrey’s teams imaged and quantified images of neoartery sections. Slides were imaged 
using an Olympus BX/51 microscope and associated Olympus DP70 digital camera, with PSR 
images taken under polarized light. Analysis of the digital images was performed using a custom 
MATLAB script that converts the original red, green, blue (RGB) images to the hue, saturation, 
lightness (HSL) color space to enable additional pixel-specific thresholding and delineation of 
individual constituents of interest, as previously described. For Picosirius red (PSR)-stained 
sections, area fractions of red, orange, yellow, and green pixels were quantified to identify the 
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relative distribution of large and small collagen fibers and differences in fibrillar collagen 
packing at each time point and throughout the 5 regions of interest. IHC images were first 
inverted, and the inverted RGB images were then converted to HSL color space, with HSL 
parameters chosen to isolate light blue pixels (H=160°-210°, S=0.1-1.0, L=0.47-1.0). Associated 
area fractions were calculated based on the total number of pixels that satisfied the HSL 
thresholding requirements for each constituent, divided by the total number of pixels identified 
as having any HSL parameter values other than those for the color black (the uniform 
background color, as established by an initial global thresholding). 
4.2.6 Statistical Analysis 
All data are presented as mean ± standard error of the mean (SEM). Differences between groups 
were analyzed using a one-way analysis of variance (ANOVA), and Bonferroni corrections were 
used to account for multiple statistical comparisons. Statistical significance was indicated by p 
values < 0.05. 
4.3 RESULTS 
4.3.1 Patency 
Graft patency appeared to correlate with implantation technique (Table 8). The exception is 
Espun PGS-PLGARemoved PCLSheath grafts. Those grafts were prone to thrombosis secondary to 
PGS core buckling from the compressive force of PCL, as we had not yet implemented the salt-
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hardening step which reduces graft compression. Implantation methods A and B showed poor 
patency rates, while method C showed substantial improvement, and D yielded 100% patency. 
Thrombosis was the cause or suspected cause of occlusion in all closed grafts. 100% patency in 
Espun PGS-PVARemoved PCLSheath grafts implanted by method D suggests favorable 
hemocompatibility of that design. However, further conclusions are difficult to draw, as graft 
blood-compatibility for other designs could not be de-coupled from any thromobgenicity 
inherent in implantation methods A-C and the surgeon’s lack of prior experience with those 
methods. 
 
 
Table 8. Patency rates for implanted grafts 
 
Implant 
Method Graft 
Occlusion 
Risk 
Patency  (%; 
Minimum  
Estimate) 
No. of 
patent 
grafts 
Time 
point 
(days) 
Observations in vivo 
A 
Espun PGS-PLGAIntact Thrombosis 0% 0   
Espun PGS-PLGARemoved PCLSheath Thrombosis 0% 0   
SCPL PGS-PCL Tearing N/A (Implant Failure) 0   
B 
Espun PGS-PLGAIntact Thrombosis 0% 0   
Espun PGS-PLGARemoved Thrombosis, Tearing 25% 1 90 n=1 Dilation 
Espun PGS-PLGARemoved PCLSheath Thrombosis, graft buckling 0% 0   
C 
Espun PGS-PLGAIntact Thrombosis 75% 3 70 n=3 Dilation, calcification 
Espun PGS-PLGARemoved PCLSheath Thrombosis, graft buckling 0% 0   
D Espun PGS-PVARemoved PCLSheath N/A 100% 9 
90 n=3; 
180 n=3; 
365 n=3 
Slowed material 
degradation, elastin 
deposition, dilation, 
calcification 
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4.3.1 Remodeling of Espun PGS-PLGA microfibers with or without PLGA removal 
The patent grafts from implantation methods A-C offer some insight into the remodeling 
potential of vascular grafts made using Espun PGS-PLGA with or without PLGA removed. Graft 
numbers, explant time points, and findings are summarized in Table 8 (columns 5-7).  Both 
Espun designs lacking PCL sheaths demonstrated substantial resorption of graft material and 
neotissue formation, but remodeled tissues were prone to dilation (Figure 38). These neoarteries 
contained regions with gross similarity to neointimal hyperplasia, largely acellular regions of 
dense matrix, and regions of chronic inflammation likely due to residual polymer. Elastin was 
not seen in neoarteries, as they were negative for elastin autofluorescence.  Mineralization was 
observed in the aneurysmal regions of grafts (Figure 39).  
 115 
 
 
 
 
Figure 38.  Gross morphology and histology of Espun PGS-PLGA grafts 
Morphology and histology of Espun PGS-PLGARemoved (left two columns) and Espun PGS-PLGAIntact microfiber 
grafts (right two columns). Neither design includes a PCL sheath. Top row: in situ and explant gross morphology. 
Inset shows midgraft transverse section. Bottom rows: H&E staining of midgraft and aneurysmal portions of 
explants. Boxed region indicates region of higher magnification shown below. White arrows denote regions of 
putative neointimal hyperplasia. Blue arrows denote putative residual graft material and associated inflammation. * 
indicates cell-poor regions comprised primarily of dense extracellular matrix. 
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Figure 39.  von Kossa staining of Espun PGS-PLGARemoved grafts at day 90 
von Kossa staining of midgraft (left) and aneurysm (right) shows mineralization (black) in aneurysmal sections. 
 
 
 
4.3.2 Dilation in Espun PGS-PVARemoved PCLSheath grafts 
Espun PGS-PVARemoved PCLSheath grafts were implanted by a surgical team at the Research 
Institute at Nationwide Children’s hospital. This team achieved 100% patency in their model. 
Neoarteries from these grafts demonstrated elastic fiber formation but also showed slower 
resorption of graft material, and experienced dilation in most cases (Figure 40 A). These grafts 
showed no evidence of thrombosis in the absence of systemic heparinization, suggesting 
favorable hemocompatibility in small diameter, high flow arterial circulation. Dilation was a 
prevalent complication. Dilation incidence over time is shown in Figure 40. At 3 months post-
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implant, 78% (7/9) of implanted grafts demonstrated dilation of over 25% the initial graft inner 
diameter.  At the 6 month time point, 83% of remaining grafts were dilated (5/6). By 1 year post-
implant, 100% (3/3) of the remaining grafts were dilated. 
 
 
 
 
 
 
Figure 40.  Dilation in Espun PGS-PVARemoved PCLSheath grafts 
A. In situ images of graft remodeling from day 0 (left) to 6 months post-implant (right column) show dilation in 
most grafts (top), with one graft remaining undilated (bottom). Red scale bar in right column images is 2 mm. 
Images taken by Tai Yi and Yong Ung-Lee. B. Incidence of graft dilation at each time point. Grafts demonstrating 
more than 25% increase in initial inner diameter (“dilated”; orange) increased proportionally at each time point, with 
100% of grafts dilated at 1 year post-implant. C. Luminal diameter of neoarteries (square) and adjacent aorta (circle) 
over the time course of the study. Diameter was measured by non-invasive ultrasound at 1, 2, 3, 4, 6, 11, and 12 
months post-implant. *’s indicate significant difference compared with the native aorta at that time point. 
 
 
 
4.3.3 Espun PGS-PVARemoved PCLSheath grafts limit cell infiltration and material resorption 
Neotissue formed primarily on the luminal and abluminal surfaces of graft material, which 
partially resorbed over the course of 1 year (Figure 41). By 3 months post-implant, substantial 
neotissue formed on the luminal surface of grafts, but the graft material was largely retained 
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except in one graft. By 6 months post-implant, much graft material resorbed, but much persisted, 
and calcification was suspected in one animal. Material residues were still present at 1 year post-
implant, with neotissue thickness varying both between and within explants. Grafts with larger 
dilations showed non-uniform wall thickness of residual graft material at 3 months. 
 
 
 
 
 
Figure 41.  Neotissue formation and material residues in Espun PGS-PVARemoved PCLSheath grafts 
H&E staining of midgraft region of neoarteries at 3 months, 6 months and 1 year. Images are arranged according to 
their maximum level of dilation at any location in the neoartery. All images are set to the same scale (scale bar 200 
µm). At 3 months, neotissue (black arrows) forms primarily on the luminal and abluminal surfaces of most grafts, 
and substantial quantities of graft material (green arrows) remain present. Graft remodeling is observed as nearly 
complete in only one animal, though some residues are still present. At 6 months, partial degradation of material is 
observed. White spaces represent the putative location of residual graft material, which likely fell out of sections 
during cutting. Calcification was suspected in some neoarteries (red arrow). At 1 year, some graft residues still 
remain, and putative calcification occurred at a higher frequency (red arrows). 
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4.3.4 Matrix architecture of neoarteries and adjacent aortas remodels over time 
Matrix architecture in neoarteries and native aortas varied over the time course of the study, 
including between 6 months and 1 year. At 3 months post-implant, elastic fibers deposited in 
neoarteries in multiple layers with structural similarity to native arteries. However, elastic fiber 
organization regressed at 6 months and 1 year post-implant (Figure 42).  Collagen deposition in 
neotissues was evident starting at 3 months post-implant, with no significant change in the ratio 
of densely packed vs. loosely packed collagen fibers over time. However, collagen composition 
of the adjacent abdominal aorta varied over the study time course. The ratio of densely packed 
collagen to looser collagen increased between 3 months and 6 months, then returned toward 
original values by 1 year post-implant (Figure 43). 
 
 
 
 
 
Figure 42.  Elastic fiber organization in neotissues of Espun PGS-PVARemoved PCLSheath grafts 
Hart’s staining of luminal neotissue in neoarteries at 3 months, 6 months, and 1 year post-implant. Elastic fibers 
stain dark purple. Modified from figure created by Cameron Best, Yong-Ung Lee, Tai Yi, and Ramak Khosravi; in 
preparation for [182]. 
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Figure 43.  Collagen fiber density of neotissues in Espun PGS-PVARemoved PCLSheath grafts 
A. Picosirius Red (PSR) staining of neoarteries and adjacent infrarenal abdominal aortas at each time point. Under 
polarized light, stained collagen fibers appear as green, yellow, orange, or red; listed in order of increasing packing 
density. Images taken at 20x magnification. L indicates neoartery lumen. B. Quantification of the area fraction of 
each collagen fiber color in adjacent infrarenal aorta (IAA), neoartery at the anastomosis, and the midgraft region of 
the neoartery (PGS graft). In adjacent aorta (IAA), the area fraction of denser collagen fibers (orange and red) 
increased at 6 months, but then reverted to 3-month levels at 1 year. Neoartery collagen fibers retained 3-month 
densities over the course of 1 year. Values are mean ± SEM. *p < 0.05, **p < 0.005, ns indicates not significant. 
Modified from figure created by Ramak Khosravi and Cameron Best in preparation for [182].  
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4.3.5 Cell distribution, inflammation, and graft mineralization 
Figure 44 summarizes the distribution of myofibroblasts (alpha-SMA+, calponin-, SM-MHC-), 
contractile smooth muscle (alpha-SMA+, calponin-, SM-MHC+), and macrophages (F4/80+) in 
neoarteries.  Graft luminal surface neotissue was rich in alpha-SMA positive cells and calponin 
positive cells at 3 months post-implant. Few of these cells were also positive for smooth muscle 
myosin heavy chain (SM-MHC), suggesting the majority are myofibroblasts or synthetic smooth 
muscle cells rather than contractile smooth muscle cells. The number of contractile smooth 
muscle cells increased from 3 to 6 months. By 12 months, SM-MHC-positive cells had re-
organized into a densely packed layer near the luminal surface of the neoartery. Macrophages 
were sparsely distributed in neoarteries at 3 and 6 months post-implant, but dramatically 
increased in number by 1 year, and localized most densely in regions surrounding putative graft 
material residues. Mineralization also tended to co-localize in regions adjacent to putative graft 
materials. Mineralized regions positive for von Kossa stain were found in all 1-year neoarteries 
(3/3), with the majority of stain found at the periphery of white spaces likely to be graft residues 
which were lost during sectioning (Figure 45). Mineralization was also found in 1/3 grafts at 3 
months and 6 months. 
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Figure 44.  Cellular distribution in neotissues of Espun PGS-PVARemoved PCLSheath grafts 
Immunohistochemical and immunofluorescent staining of neoarteries for alpha-smooth muscle actin (α-SMA; 
brown), calponin (brown), smooth muscle myosin heavy chain (SM-MHC; red), and F4/80 (brown). Top row: α-
SMA is present in the luminal surface of neotissues throughout the time course. Second row: calponin stains many 
cells in the luminal surface of neotissues, though it does not co-localize with all α-SMA+ cells. Third row: SM-MHC 
is sparse at 3 months post-implant, but is more common at 6 months, and becomes concentrated into several dense 
cellular layers by 1 year post-implant. Bottom row: F4/80 staining marks macrophages, which are sparse at 3 months 
and 6 months, but densely populate neoarteries at 1 year post-implant.  F4/80 is most concentrated at the periphery 
of regions devoid of any stain (arrow), which are likely to be residual graft material which was lost during 
sectioning. L indicates vessel lumen. 
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Figure 45.  Mineralization in neotissues of Espun PGS-PVARemoved PCLSheath grafts 
von Kossa staining shows mineralization (black stain indicated by red arrows) in 5/9 neoarteries. Blue arrows denote 
the likely location of graft residual material. At 1 year post-implant (bottom row), all neoarteries show 
mineralization, with the majority co-localized with the edges of putative graft residues (blue arrows). Scale bars 200 
µm, except for the 6 month neoartery with calcification, for which the scale is 500 µm. Modified from figure created 
by Cameron Best, Yong-Ung Lee, Tai Yi, and Ramak Khosravi; in preparation for [182]. 
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4.4 DISCUSSION 
This chapter summarizes our efforts to assess the in vivo performance of our electrospun designs 
for bio-inductive vascular grafts. Despite the advantages of electrospinning as a fabrication 
technique for vascular grafts, relatively few research groups have investigated such designs in 
vivo ([163] for review). We identified that the majority of materials used were slow-resorbing 
polymers. Some teams have also electrospun natural materials such as collagen and soluble 
elastin [183], or proteins which simulate their properties [184], in order to better stimulate the 
mechanical and biological properties of native arteries. Our design departs from the others tested 
in that it is made primarily from a fast-resorbing elastomer. Further, our material has already 
demonstrated in vivo hemocompatibility and fast-remodeling, as described in [118] and Chapter 
2. Consequently, we expected our electrospun microfiber grafts to match or exceed the patency 
and remodeling potential of previously reported electrospun vascular grafts. 
Low patency rates were seen in the first 32 implants, likely resultant from our surgeon’s 
lack of microsurgery training or prior experience in the animal model. Consequently, we were 
unable to assess patency as a function of graft design in those implants. Further, in-host 
remodeling could only be assessed in the few patent grafts, which included only four samples 
split between two groups (Espun PGS-PLGAIntact [n = 3 at 70 days], and Espun PGS-
PLGARemoved [n = 1 at 90 days]).  
Espun PGS-PLGAIntact and PGS-PLGARemoved grafts extensively remodeled into 
neotissues with few material residues by 90 days post-implant. The mechanism of remodeling 
likely differs from that of SCPL PGS-PCL. Due to small pore size and fusion between fibers, 
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Espun PGS-PLGAIntact and PGS-PLGARemoved grafts likely limit the deposition of provisional 
matrix and initial myeloid cell infiltrate to the luminal and abluminal surfaces of the graft. 
Consequently, the total amount of provisional matrix and initial cellular infiltrate in the acute 
phase should be less in Espun PGS-PLGAIntact or Removed grafts than in SCPL PGS-PCL grafts. In 
turn, the capacity of Espun PGS-PLGAIntact or Removed grafts to recruit macrophages, synthetic 
cells, and stem/progenitor cells should be reduced. The result of lower early macrophage 
recruitment would likely be less subsequent recruitment of synthetic cells and other 
macrophages, and slower degradation of the graft material, which would be further slowed by the 
inability of recruited macrophages to infiltrate beneath the graft’s outer surface until more 
surface erosion takes place. Fewer synthetic cells could reduce the rate of matrix deposition 
within the graft. The net result may be a slower graft remodeling process in Espun PGS-
PLGAIntact or Removed than in SCPL PGS-PCL. Despite the likely slower remodeling process, Espun 
PGS-PLGAIntact or Removed grafts generated neovessels with few material residues remaining within 
70 days. This result corroborates previous findings that nonporous but fast-resorbing vascular 
grafts can form neoarteries [113, 114, 139]. 
A slower remodeling process in Espun PGS-PLGA grafts may explain differences in 
resultant neoarteries compared to those formed from SCPL PGS-PCL grafts.  The discrepancies 
included dilation, absence of elastin, and regions of dense matrix with few cells. Dilation could 
be a result of slower matrix deposition in Espun PGS-PLGA neoarteries. Slower material 
degradation may further limit matrix deposition; both espun PGS-PLGAIntact and PGS-
PLGARemoved grafts are stiffer than SCPL PGS-PCL grafts, thereby shielding synthetic cells from 
physiological cyclic strains known to promote matrix deposition [26, 27] including insoluble 
elastin [28]. PGS has previously promoted elastin deposition in vitro [121, 185] and in vivo [118, 
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135], which is thought to be due to its similarity to arterial mechanical properties [185]. Stiffer 
PGS might not produce the same effect. In support of this hypothesis, we did detect elastin 
deposition in Espun PGS-PVARemoved PCLSheath grafts, which are the closest to arteries in 
mechanical properties out of the electrospun grafts we implanted. However, these grafts were 
also implanted into a mouse rather than rat model, so direct comparisons to the other grafts 
should be made with caution. Alternatively, the absence of neoartery elastin in some electrospun 
grafts could also be due to differences in the ability of PGS-based microfibers to adsorb 
tropoelastin compared with SCPL PGS. This is an active area of investigation in the Weiss 
laboratory in collaboration with our own. Regions of dense matrix could be caused by several 
features of Espun PGS-PLGA-based grafts. Longer residence time of macrophages in the slow 
degrading graft could promote the formation of dense collagen-rich matrix seen in traditional 
foreign body responses [142]. Dense matrix deposition and reduction in cell density in the 
neomedia could also be secondary to aneurysmal dilatation, as both occur in the natural 
pathohistology of aortic aneurysms [186]. Toxicity from residual lysine triisocyante cross-linker 
or LiBr salt could have also contributed to cell death in these matrix-dense regions. 
We applied PCL fiber sheaths to some microfiber grafts primarily to improve surgical 
handling by improving suture retention strength. Prior to conducting implantations, we also 
acknowledged that the PCL sheath may serve the additional function of providing mechanical 
support while the graft remodels. This structural safety net could protect grafts from dilation or 
aneurysm if the neotissue is unable to sustainably bear load as the graft core resorbs. However, 
our team had never tested this theory. Our previous use of SCPL PGS constrained our grafts to 
require PCL sheaths to render them suturable. By developing PGS microfibers with adequate 
surgical handling, we were able to implant some grafts without PCL sheaths for the first time. 
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Espun PGS-PLGAIntact grafts demonstrated adequate surgical handling without a PCL sheath, 
and remodeled into neotissues with minimal graft residues remaining at 70 days post-implant. 
However, all PGS-PLGAIntact neoarteries demonstrated substantial dilation. Similarly, the Espun 
PGS-PLGARemoved graft also remodeled, but it dilated and formed an aneurysm at the distal 
anastomosis. Our tentative conclusion was that a PCL sheath is needed required prevent graft 
dilation in fast-remodeling bio-inductive grafts. Our initial attempts to apply a PCL sheath to 
Espun PGS-PLGARemoved grafts compressed the PGS cores, causing buckling of the lumen during 
surgical manipulation. To reduce propensity buckling failure, we temporarily impregnated PGS 
cores with NaCl crystals prior to applying the PCL sheath, as described in 3.2.5. This technique 
appeared to prevent buckling failure in Espun PGS-PVARemoved PCLSheath grafts, which we 
selected for more extensive study. 
Multiple time points and thorough histological characterization are required to understand 
the time course of graft inflammatory response, cell infiltration, and matrix deposition. For grafts 
1 through 32, low patency rates prevented our team from attaining the sample sizes required to 
sacrifice at multiple times. In rodent interpositional vascular grafting, patency is largely a 
function of surgical technique. To improve patency rates, we began collaborating with a team of 
experienced microsurgeons in the Breuer laboratory at the Research Institute of Nationwide 
Children’s Hospital. We provided the team with Espun PGS-PVARemoved PCLSheath grafts, which 
was our most translatable graft design at the time. The team successfully implanted these grafts 
at 100% implant success and patency. This collaboration enabled graft patency and remodeling 
time course to be adequately assessed. 
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Espun PGS-PVARemoved PCLSheath grafts formed artery-like neotissues on the luminal 
surface of grafts, which retained the majority of graft material at 3 months post-implant. The 
remodeling process was likely similar to that of Espun PGS-PLGAIntact or Removed grafts, except for 
three differences: (1) Graft material degradation was likely limited to the luminal surface, 
because the slow degrading PCL sheath likely limits phagocyte-mediated graft degradation on 
the abluminal surface of the graft; (2) The graft core material is substantially closer in Young’s 
modulus to that of native arteries; and (3) There is minimal risk of toxicity from graft residues, as 
Espun PGS-PVARemoved PCLSheath grafts contain no chemical cross-linkers or toxic salts, and are 
purified using water and ethanol. 
Neotissue formation in Espun PGS-PVARemoved PCLSheath grafts reflects these differences 
in the remodeling process from Espun PGS-PLGAIntact or Removed grafts. At 3 months, these 
neotissues contained elastic fibers, likely due to closer mechanical matching between graft 
material and native arteries. Neotissues in Espun PGS-PVARemoved PCLSheath contained 
substantial quantities of α-SMA+ cells at 3 months post-implant, which are likely responsible for 
this elastic fiber production. α-SMA+ cells at 3 months likely include a combination of 
myofibroblasts (α-SMA+, Calponin-, SM-MHC-) [187] and synthetic vascular smooth muscle 
cells (α-SMA+, Calponin-, SM-MHC-) [188], with few contractile cells present (SM-MHC+). 
[188]. Adult synthetic vascular smooth muscle cells have been shown to produce tropoelastin, 
the bulk component of elastin, as well as and fibrillin-1 in vitro [121]. Myofibroblasts may also 
produce elastic fiber components [189]. While elastic fiber formation at 3 months was 
encouraging, elastic fibers appeared less organized at 6 months and 12 months post-implant. 
Slowed material degradation may have contributed to fiber degeneration by prolonging the 
presence of macrophages. Macrophages can secrete MMP’s and reactive oxygen species which 
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damage elastic fibers. [190, 191] At 1 year post-implant, macrophages (F4/80+) dramatically 
increased in population, consistent with this theory.  
At 1 year post-implant, many of the remaining α-SMA+ cells were also SM-MHC+, 
suggesting their differentiation toward, or replacement with, contractile smooth muscle cells. 
Contractile smooth muscle produces negligible components of elastic fibers and is unlikely to 
sufficiently repair the damaged elastic network. The presence of contractile smooth muscle is 
encouraging from the perspective of avoiding stenosis by neointimal hyperplasia, as it is instead 
the synthetic phenotype that is responsible for proliferating and migrating into the neointima 
[188]. However, the presence of large quantities of macrophages at 1 year post-implant poses a 
risk for de-differentiation of contractile smooth muscle back toward synthetic phenotypes. In 
atherosclerosis, macrophages secrete PDGF which promotes smooth muscle migration and 
proliferation [191].   
Dilation occurred at high incidence in Espun PGS-PVARemoved PCLSheath grafts. Dilation is 
a potentially serious complication, as in some cases dilation can lead to graft rupture or other 
aneurysmal pathologies. We were surprised to observe dilation at such high incidence, as we 
applied a slow-resorbing PCL sheath to the Espun PGS-PVARemoved core to prevent dilation. 
However, dilation of the graft’s luminal neotissue could still occur in the presence of a non-
dilating outer sheath. The cause of dilation was likely the gradual erosion of the luminal surface 
of the PGS-PVARemoved core, which subsequently allowed the neotissue on the graft’s luminal 
surface to dilate. In this model, the graft’s neotissue would continue to dilate until reaching the 
PCL sheath. Indeed, the dilation of neoartery inner diameter rarely exceeded the diameter of the 
PCL sheaths of the grafts (1.16 mm). Aneurysmal dilatation was observed in some grafts, which 
could be due to retraction of the PCL sheath at the anastomoses during surgical handling. To 
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prevent dilation in future designs, grafts could be constructed with reduced wall thickness of the 
core, thereby setting the PCL sheath to a diameter closer to the desired final diameter of the 
neoartery. Aneurysm at the anastomoses could be avoided by preventing delamination of the 
PCL sheath from the PGS core using biodegradable adhesive. 
Despite the prevalence of graft dilation, most Espun PGS-PVARemoved PCLSheath grafts 
demonstrated elastin-rich neotissues on their luminal surfaces at 3 months post-implant. Elastic 
fibers protect healthy arteries by conferring elastic recoil to arteries, thereby preventing dynamic 
tissue creep from arterial pressurization [192]. It is likely that despite its presence, the elastin was 
not mechanically functional. Indeed, in the case of nonfunctional elastin, neoarteries would be 
prone to dilation by collagen fatigue [193]. Residual PGS graft material is also prone to creep in 
this graft design, as we found Espun PGS-PVARemoved cores to deform plastically at the thermal 
cross-linking conditions used in this study [169]. 
Calcification was observed in all Espun PGS-PVARemoved PCLSheath grafts, and was most 
prevalent at 1 year post-implant.  Calcification was most prevalent along the surface of residual 
graft material, co-localized with both F4/80+ macrophages and α-SMA+ myofibroblasts and 
smooth muscle cells. One potential mechanism is smooth muscle cell transdifferentiation into 
chondrocytes, as observed in atherosclerosis and by de Valence et al in electrospun PCL vascular 
grafts [138]. The co-localized macrophages may be driving the process by mediating smooth 
muscle apoptosis and transdifferentiation into osteoblast-like cells, as occurs in atherosclerosis 
[194, 195]. 
We originally hypothesized that electrospun microfibrous vascular grafts made with PGS 
would retain the excellent long-term performance observed by the SCPL PGS-PCL design. 
Taken together, our results refute this hypothesis. However, the findings do not necessarily refute 
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our central hypothesis that grafts must remodel rapidly to form functional neoarteries rather than 
a traditional foreign body response. Rather, these results clarify that pore size likely determines 
the rate at which grafts can remodel. Thus the central hypothesis can be refined to state that in 
order for a vascular graft to remodel rapidly, it must (1) be comprised of a material with the 
capacity to degrade rapidly in vivo, and (2) it must possess pores large enough for phagocytic 
cells to infiltrate in sufficient number to realize such rapid degradation. 
 
4.5 LIMITATIONS AND FUTURE DIRECTIONS 
Future work will address the limitations of this study. The rate of graft remodeling was likely 
limited in all microfiber grafts by small pore size. Increasing pore size would increase the 
number of cells captured by the graft, thereby improving the rate at which neotissue forms and 
graft material resorbs [163]. Restoring pore size to that of SCPL PGS-PCL grafts (21 µm 
diameter) would likely restore the rate and quality of graft remodeling. Efforts are currently 
underway to increase pore size by altering electrospinning parameters. In new unimplanted 
second generation designs, we have already demonstrated that pore size can be doubled by 
tuning electrospinning parameters (Figure 46). PGS microfibers made from PVA blends 
resorbed substantially slower than those made from PLGA blends. PVA blends had the simplest 
and most rapid fabrication with the least potential for cytotoxicity, so efforts to accelerate their in 
vivo degradation could yield the most translatable graft. In addition to increasing pore size, 
reducing the curing temperature can also accelerate hydrolytic degradation rate (Figure 47). 
Consequently, we are constructing our second generation PVA-based microfiber grafts using 
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thermal crosslinking at 120 ºC for 48 h. Fibers made at this curing condition also have the added 
benefit of elastic deformation [169], thus providing additional resistance to aneurysmal 
dilatation. 
Early stage graft remodeling is unknown, as the present study did not investigate the graft 
remodeling process earlier than 70 days post-implant. Assessing graft remodeling within this 
window could provide crucial insights into the mechanics of neotissue formation. The role of 
inflammatory cells in particular should be analyzed, as work by the Breuer laboratory has 
suggested that infiltrating macrophages promote neotissue formation and improve patency by 
releasing cytokines and growth factors [158]. The origin and retention of cells populating the 
neoartery is also unclear in the present study. Methods such as bone marrow labeling could track 
the proportion of cells that come from circulation, as well as their long-term retention. Lastly, the 
true in vivo performance of Espun PGS-PLGAIntact or Remodeled grafts is unknown, as the surgeon 
who performed those implantations used a technique with high complication rates.  Providing 
this graft design to the Nationwide Children’s Hospital team could elucidate in vivo performance, 
but we chose to forego such testing because PLGA blends are limited in translational potential 
by their lengthy fabrication method and potential for cytotoxicity. 
 
 
 
 
 133 
 
 
 
Figure 46.  Comparison of 1st and 2nd generation Espun PGS-PVARemoved grafts 
SEM images compare the structure of first generation electrospun grafts (1st gen; left) with a second generation 
design (2nd gen; right) optimized for remodeling potential and surgical handling. Magnification is identical in each 
row, allowing for side-by-side comparison of geometry. Second generation grafts demonstrate substantially 
increased pore size to enhance cell infiltration, and have reduced inner diameter and wall thickness to better match 
the native mouse aorta. Scale bar 250 µm for first row, and 25 µm for second row. 
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Figure 47.  Effect of curing conditions on hydrolytic degradation of Espun PGS-PVARemoved microfibers 
Fraction of mass remaining (mass fraction) vs. incubation time for Espun PGS-PVARemoved microfibers thermally 
cross-linked under first generation conditions (120 ºC 24h, 150 ºC 24h; square with dotted line) and second 
generation conditions (120 ºC 48h; circle with solid line). Disks of graft cores were incubated in pH 11.75 buffer at 
37 °C with agitation to accelerate hydrolysis in vitro. 2nd gen microfibers resorbed at twice the rate of 1st gen 
microfibers in these conditions. Error bars represent standard deviation. Error bars are not shown for 1st gen grafts, 
as they are smaller than the markers used. *P < 0.01. 
 
 
 
4.6 CONCLUSION 
This chapter investigated the in vivo performance of the electrospun PGS grafts developed in 
Chapter 3. Electrospun grafts demonstrated substantial in-host remodeling, but did not replicate 
the likeness to native arteries realized by the SCPL PGS-PCL design. Small pore size likely 
prevented cell infiltration in all microfiber designs, and may explain the persistence of graft 
residues in Espun PGS-PVARemoved PCLSheath microfiber designs. Increasing pore size and 
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adjusting thermal crosslinking conditions might restore the fast-remodeling potential of these 
grafts. Preventing PCL sheath disruption at the anastamoses could also protect grafts from 
aneurysmal dilatation. These future directions are areas of active investigation by our laboratory. 
Their successful implementation could restore the fast-remodeling potential of the grafts, thereby 
empowering us to leverage the potential translational advantages that microfiber grafts hold over 
SCPL vascular grafts. 
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5.0  OUTLOOK AND FINAL SUMMARY 
The long-term objective of this body of work is to improve the clinical performance of vascular 
grafts. To achieve this objective, we employed next generation materials to revitalize a strategy 
developed by a previous generation: fast-remodeling bio-inductive vascular grafts. After proving 
the concept in 2012, our short term objective became to investigate the translational potential of 
our fast-remodeling bio-inductive design. To this end we began an iterative process of 
performance testing and redesign, with usability and fabrication throughput as new design 
criteria.  
The work described in this dissertation represents 1.5 cycles of the iterative design and 
validation process. Herein we tested the long-term performance of our initial prototype (Chapter 
2), adjusted the design for enhanced usability and fabrication throughput (Chapter 3), and 
repeated performance testing (Chapter 4). We succeeded in improving surgical handling and 
fabrication throughput, but at the cost of in vivo performance. Further iterations are required to 
concurrently realize favorable performance, usability, and ease of fabrication. This dissertation 
represents an important first step in design optimization which critically informs the next set of 
experiments. Importantly, our findings should also constructively influence others pursuing bio-
inductive vascular graft designs, as well as impact the broader fields of tissue engineering and 
regenerative medicine. 
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5.1 SCPL PGS COMPOSITES - IMPACT AND OUTLOOK 
We previously demonstrated that fast-resorbing bio-inductive vascular grafts made with SCPL 
PGS remodel into neoarteries with few material residues retained within 3 months [118]. In this 
dissertation, we further demonstrated that neoartery remodeling continues between 3 months and 
1 year, despite the presence of elastin, mechanical compliance, and the absence of most graft 
materials. This key cautionary finding should influence others in the field to extend the duration 
of their in vivo experiments, as it suggests that neoarteries continue to remodel long after the 
majority of material residues resorb. The difference in short-term and long-term results may be 
even more pronounced in patients with cardiovascular disease, whose native arteries remodel 
pathologically without insult. 
Despite favorable performance, the translational potential of SCPL PGS is low. We 
quantified the limitations of SCPL fabrication in Chapter 2 (Figure 34). While SCPL PGS may 
have limited translational potential, it has virtually unlimited research potential. In the hands of 
an experienced microsurgeon, composite vascular grafts containing SCPL achieve near-ideal in 
situ remodeling in small animals. Understanding this process could empower the field to 
reproduce or improve it in more translatable graft designs. Determining the identity, origin, and 
role of each participating cell type would enable rational design of strategies to induce or 
enhance these processes in translatable grafts.  
To ensure that findings in SCPL grafts are relevant to the clinical situation, future studies 
should supplement the rat abdominal aorta interposition model with more clinically relevant 
animal models. Aged animals with cardiovascular disease, diabetes, and/or renal dysfunction 
should be used to simulate various clinical situations, and are likely to demonstrate altered in situ 
remodeling processes. Large animal models also better simulate human hemodynamics and 
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healing potential, although there is debate about which best represents the clinical situation.  
Also critical to simulate is clinically relevant vascular graft lengths, which are on the order of 
many inches to feet. Long grafts are difficult to fabricate with SCPL PGS, as crack-like defects 
form at a rate that scales with length and thickness. To simulate remodeling in the central region 
of long grafts, shorter SCPL grafts could be implanted in a novel rat model. The model 
anastomoses a loop of ePTFE graft to each aortic stump, then bridges the gap between ePTFE 
grafts with the test graft. The ePTFE loops prevent host cells at the native aorta anastomoses 
from migrating into the graft, thereby simulating the clinical situation presented at the central 
region of long vascular graft [196]. This model could provide crucial in vivo insights, but is no 
substitute for implanting long grafts in a large animal. Our impending need to produce longer 
grafts was a major driver for our pursuit of more versatile graft fabrication methods. 
5.2 ESPUN PGS MICROFIBER COMPOSITE - IMPACT AND OUTLOOK 
In Chapter 3 we demonstrated that electrospinning microfiber fabrication improves the surgical 
handling, fabrication throughput, and reproducibility of microfibrous PGS vascular grafts. This 
achievement enabled us to develop and implant novel vascular graft designs with handling and 
fabrication advantages over SCPL composite grafts, as described in Chapter 4. Importantly, 
electrospinning also enables us to fabricate larger and longer vascular grafts for large animal 
studies, which are substantially more challenging to construct from SCPL structures. More 
broadly, facile construction of electrospun PGS microfibers could profoundly impact the fields 
of biomaterials, tissue engineering, and regenerative medicine. To our knowledge, this technique 
is the first to yield PGS scaffolds capable of withstanding the suture anchoring and tensile 
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loading required of most in vivo applications [169]. PGS has long been considered a desirable 
biomaterial for soft tissue applications due to its soft and elastic mechanical properties, rapid 
resorption in vivo by surface erosion, biocompatibile degradation products, and muted 
inflammatory response [162]. Facile implantation of PGS microfibers will empower the 
scientific community to apply PGS toward solving a range of medical problems.  
Our in vivo performance study in Chapter 4 demonstrated both constructive and 
pathological remodeling in microfibrous PGS grafts. This is clearly a reduction in performance 
compared with the original SCPL design. The key difference in graft properties between 
electrospun PGS and SCPL PGS is reduced porosity (47.1 vs. 81.1%) and pore size (1.87 vs. 
21.2 µm), which likely inhibited cell infiltration and thereby slowed material resorption and 
induced chronic inflammation in microfibrous PGS. By demonstrating the importance of pore 
size even in fast-resorbing materials, this work should inform the design of other fast-resorbing 
bio-inductive implants.  In light of the limited neotissue formation of electrospun PGS-based 
grafts, the SCPL PGS-PCL composite graft developed in Aim 1 remains the best-performing 
graft of all those developed in this dissertation work. However, we expect that with increased 
pore size, microfibrous PGS grafts can supersede SCPL PGS-PCL grafts in translational 
potential. Increasing pore size in electrospun PGS grafts should enhance cell infiltration, thereby 
enabling graft remodeling to approach or match that seen in SCPL PGS-PCL grafts, whilst 
retaining the advantages of electrospinning fabrication. Table 9 summarizes the advantages and 
limitations of each graft developed in this work, and includes recommended strategies for 
overcoming each limitation. Our team is already applying our learnings to the next graft design. 
At present we are leveraging the versatility of electrospinning to increase porosity and pore size, 
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which could improve the in-host remodeling in the electrospun PGS-PVARemoved-PCL grafts 
(Figure 46). 
Table 9. Summary of graft designs 
 
Graft* Core Sheath Advantages Limitations Mitigation Strategies 
SCPL PGS-PCL SCPL PGS 
Electrospun 
PCL micro- and 
nano-fibers 
Cell infiltration Requires gentle surgical handling Thicken PCL sheath 
Rapid material 
clearance 
High rate of 
fabrication defects 
Process development for SCPL 
technique 
Constructive graft 
remodeling 
Fabrication requires 
manual labor 
Process development and quality 
control strategies for SCPL 
technique 
Neoartery 
compliance and 
tissue architecture 
differs from native 
Modulate cell infiltration and 
matrix deposition with local protein 
delivery 
Electrospun PGS-
PVARemoved-PCL 
Electrospun 
PGS with PVA 
carrier removed 
Electrospun 
PCL micro- and 
nano-fibers 
Surgical handling 
Cell infiltration Increase pore size 
Slow material 
degradation 
Increase phagocyte infiltration – by 
increasing pore size 
Simplest fabrication 
Dilation 
Increase matrix deposition – by 
increasing synthetic cell infiltration 
– by increasing pore size 
Reduce wall thickness of core 
Calcification at 1 
year post-implant 
Ensure material resorption by 1 
year  - by increasing synthetic cell 
infiltration – by increasing pore 
size 
Electrospun PGS-
PLGAIntact 
Electrospun 
PGS with 
PLGA carrier 
intact 
None Simpler fabrication than SCPL PGS-PCL 
Thrombosis (blood 
compatibility 
unknown) 
Blood compatibility testing 
Antithrombogenic surface 
modification 
Compliance 
mismatch Remove PLGA 
Cytotoxicity 
(isocyanate and 
LiBr) 
Additional water and ethanol 
washes to quench isocyanate and 
remove leachables 
Limited cell 
infiltration 
Increase pore size 
Reduce fiber fusion – by increasing 
ratio of PLGA to PGS in blend 
Dilation 
Increase matrix deposition – by 
increasing synthetic cell infiltration 
– by increasing pore size 
Reduce wall thickness of core 
Electrospun PGS-
PLGARemoved 
Electrospun 
PGS with 
PLGA carrier 
removed 
None Simpler fabrication than SCPL PGS-PCL 
Suture pull-through 
during implantation Apply PCL sheath 
Limited cell 
infiltration 
Increase pore size 
Reduce fiber fusion – by increasing 
ratio of PLGA to PGS in blend 
Dilation 
Increase matrix deposition – by 
increasing synthetic cell infiltration 
– by increasing pore size 
Reduce wall thickness of core 
Thrombosis (blood 
compatibility 
unknown) 
Blood compatibility testing 
Antithrombogenic surface 
modification 
*Listed in descending order of potential for clinical translation 
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5.3 FINAL SUMMARY 
The ideal vascular graft should be readily available at low cost, yet perform as well as a living 
artery. A cell-free, fast-remodeling bio-inductive vascular graft could fit these criteria and 
profoundly improve upon current graft performance. First-generation designs of fast-resorbing 
vascular grafts are already in human clinical trials, indicating that a range of stakeholders 
embrace the clinical promise of a bio-inductive design. The work in this dissertation represents 
an important step forward in our efforts to understand and improve the translational potential of a 
PGS-based bio-inductive vascular graft.  Insights from this work will help our team and others to 
improve designs for vascular grafts and other implants. Our team has already begun applying our 
learnings toward a next generation electrospun design which could realize the performance, 
usability, and fabrication criteria required for clinical translation. Though further design 
iterations are undoubtedly required, this dissertation work brings the research community closer 
to delivering an impactful solution to a major clinical problem. 
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